MAY 2016

MEDICAL UNIVERSITY OF SOUTH CAROLINA

COLLEGE OF MEDICINE

CURRICULUM VITAE

NAME: Elizabeth Garrett-Mayer BIRTH DATE: August 16, 1972

HOME ADDRESS: Mt Pleasant, SC 29466 HOME PHONE: 843-416-8243

OFFICE ADDRESS: OFFICE PHONE: 843-792-7764

Rm 118G OFFICE FAX: 843-792-4233

Hollings Cancer Center EMAIL: garrettm@musc.edu

86 Jonathan Lucas St. WEBPAGE: http://people.musc.edu/~elg26

Charleston, SC 29466

CITIZENSHIP AND/OR VISA INFORMATION: United States Citizen

EDUCATION:

INSTITUTION/LOCATION YEARS DEGREE/DATE FIELDS OF STUDY

Bowdoin College, Brunswick, ME 1990-1994 B.A., May 1994 Mathematics, Economics (Minor: Classics)

Johns Hopkins University, Baltimore, MD 1994-2000 PhD., Feb 2000 Biostatistics

Dissertation: Graphical Diagnostic Tools for Standard Latent Class and Latent Class Regression Model Assessment with an

Application in Describing Depression and Validating Diagnostic Criteria for Depression.

Advisor: Scott L. Zeger

Thesis Committee: William Eaton, Scott Zeger, Kung-Yee Liang, Peter Pronovost, Leon Gordis

FACULTY APPOINTMENTS:

YEARS RANK INSTITUTION DEPARTMENT

2000-2001 Instructor Johns Hopkins University Oncology

2000-2001 Joint Appt., Instructor Johns Hopkins University Biostatistics

2001-2007 Assistant Professor Johns Hopkins University Oncology

2001-2007 Joint Appt., Asst. Professor Johns Hopkins University Biostatistics

2007- 2012 Associate Professor Medical University of South Carolina Public Health Sciences*

2012- 2014 Professor Medical University of South Carolina Public Health Sciences*

2015 – present Professor with tenure Medical University of South Carolina Public Health Sciences* * formerly the Department of Biostatistics, Bioinformatics and Epidemiology; and formerly the Division of Biostatistics and Epidemiology in the Department of Medicine.

ADMINISTRATIVE APPOINTMENTS: YEARS POSITION INSTITUTION DEPARTMENT

2007 -- present Director of Biostatistics Hollings Cancer Center, MUSC

2015 – present Biostatistics & Bioinformatics Division Director Medical University of South Carolina Public Health Sciences

MEMBERSHIP IN PROFESSIONAL/SCIENTIFIC SOCIETIES:

NATIONAL SOCIETIES MEMBERSHIP

The American Statistical Association

The International Biometric Society

The Society for Clinical Trials

American Association of Cancer Research

American Society of Clinical Oncology

Translational Breast Cancer Research Consortium

NATIONAL SOCIETIES OFFICES HELD

Track Leader for Biostatistics, Scientific Planning Ctte, American Society of Clinical Oncology, 2009

ELIZABETH GARRETT-MAYER PAGE 2 OF 31 MAY 16

Local Societies MEMBERSHIP:

South Carolina Chapter of the American Statistical Association

EDITORIAL POSITIONS:

ASSOCIATE EDITOR, Clinical Trials, 2007 – present

EDITORIAL BOARD MEMBER, Cancer, 2014 - present

REFEREE FOR PEER-REVIEW JOURNALS:

1. Alzheimers and Dementia,

2. American Journal of Epidemiology

3. Annals of Internal Medicine

4. Annals of Oncology

5. Antimicrobial Resistance and Infection Control

6. Behaviormetrika

7. Bioinformatics

8. Biometrical Journal

9. Biometrics

10. Biometrika

11. Biostatistics

12. Breast Cancer Research and Treatment

13. Cancer Management

14. Cancer Research

15. Clinical Cancer Research

16. Clinical Investigation

17. Clinical Trials

18. Contemporary Clinical Trials

19. Functional and Integrative Genomics

20. JAMA Oncology

21. Journal of Clinical Oncology

22. Journal of the National Cancer Institute

23. The Journal of Nutrition

24. Journal of Applied Statistics

25. Journal of the American Statistical Association (JASA)

26. Journal of Biopharmaceutical Statistics

27. Journal of Clinical Oncology

28. Journal of the National Cancer Institute

29. Journal of Probability and Statistics

30. Journal of Psychosocial Oncology

31. Journal of the Royal Statistical Society

32. Molecular Cancer Therapeutics

33. Pharmaceutical Statistics

34. PLOS ONE

35. Statistics in Medicine

36. Trends in Pharmacological Sciences

NATIONAL ADVISORY BOARD ACTIVITIES AND COMMITTEES

ENAR International Biometrics Society Student Paper Awards Committee, 2006-2009

Translational Breast Cancer Research Consortium, Co-leader of Biostatistics, 2007-present

Scientific Planning Committee, American Society of Clinical Oncology, 2007-2010

National Cancer Institute and Investigational Drug Steering Committee, Task Force on Clinical Trial Design, 2008-2010.

Education Committee for AACR Annual Meeting, Chicago, IL 2011- 2012

Program Committee, Society for Clinical Trials Annual Meeting, Biometrics Section. Miami, FL. May 2012.

American Society of Clinical Oncology, Breast Cancer Working Group Member for the “Blueprint Project: Determining when

Outcomes of Trials Are Clinically Meaningful”, 2012- 2014.

National Cancer Institute’s Investigational Drug Steering Committee (IDSC), Biostatistics Subject Matter Expert, 2012-present.

National Cancer Institute’s Investigational Drug Steering Committee (IDSC), Clinical Trial Design Task Force, 2013-present.

American Society of Clinical Oncology, Cancer Research Committee. 2014 - 2017

American Society of Clinical Oncology, Scientific Program Committee (Biostatistics). 2015 – 2018.

American Society of Clinical Oncology, Cancer Research Committee. 2015 – 2018.

ELIZABETH GARRETT-MAYER PAGE 3 OF 31 MAY 16

Friends of Cancer Research, Working Group for 8th Annual Conference on Clinical Cancer Research. Sept – Nov 2015.

American Society of Clinical Oncology -Friends of Cancer Research Eligibility Criteria Planning Group and Working Group.

December 2015 – present

American Association of Cancer Research, Continuing Medical Education Committee. 2016 – 2018.

Accelerating Anti-Cancer Agent Development and Validation Workshop, Fundamentals Course (for training Patient Advocates).

Planning Committee Member.

NATIONAL GRANT REVIEW ACTIVITIES

2002 Reviewer, California Breast Cancer Research Program Grant Applications

2007 Reviewer, Susan G. Komen for the Cure Focused Areas of Study Program Grants

2008 Reviewer, Susan G. Komen for the Cure Promise Grants

2009 - 2011 Member & Reviewer, Scientific Peer Review Ctte, Susan G. Komen for the Cure, Promise Grants

2009, Jun Reviewer, National Cancer Institute, Specialized Programs of Research Excellence (SPORE)

2009, Sep Reviewer, National Cancer Institute, Specialized Programs of Research Excellence (SPORE)

2009 Reviewer, Susan G. Komen for the Cure, Targeted Therapies

2010, Feb Reviewer, National Cancer Institute, Specialized Programs of Research Excellence (SPORE)

2011, Jan Reviewer, Susan G. Komen for the Cure Career Catalyst Research Award Program

2011, Jan Reviewer, The ASCO Cancer Foundation Career Development and Young Investigator Awards Program

2011, Sep Reviewer, Clinical Oncology Study Section, National Institutes of Health.

2011- 2014 Executive Committee Member, Grants Selection Committee, Conquer Cancer Foundation of the

American Society of Clinical Oncology

2011, Oct Ad Hoc Reviewer, National Cancer Institute, Clinical Oncology Study Section.

2011, Feb Ad Hoc Reviewer, National Cancer Institute, Clinical Oncology Study Section

2012 – 2016 Member, National Cancer Institute, Clinical Oncology Study Section

2014, Dec Peer Review Panel Member, Department of Defense Congressionally Directed Medical Research Programs

LOCAL GRANT REVIEW

MUSC-Wake Forest Cancer Prevention and Control Pilot Project Review Committee, 2007

American Cancer Society Institutional Research Grants, 2007 – present

Hollings Cancer Center Translational Research Grants, 2008-2011

Hollings Cancer Center Tobacco Control and Tobacco-Caused Cancer Research Grants, 2011

Hollings Cancer Center Pilot Projects, 2012-present

PROFESSIONAL MEETING SESSION CHAIR

Organizer and Chair, Eastern North American Region (ENAR) International Biometrics Society Annual Meeting: "Methods

for Combining Gene Expression Datasets from Different Studies", 2004

Organizer and Chair, Society of Clinical Trials Annual Meeting. “Frequentist, Bayesian and Likelihood Designs for a Phase

II Cancer Trial with a Time-to-Event Endpoint: Head to Head Comparison of Three Philosophies of Trial Design.”

Vancouver, BC. May 17, 2011.

Organizer and Chair, American Association of Cancer Research Annual Meeting. “Phase II Trials: Are We Asking Too

Much?” Chicago, IL. March 30, 2012.

Organizer and Chair, Southern Regional Conference on Statistics (SRCOS). “Novel Dose Finding Designs in Clinical Trials.

Jekyll Island, GA. June 4-6, 2012.

Organizer, “Early Phase Adaptive Trial Designs Workshop.” Charleston, SC. October 2014

EXTERNAL DATA SAFETY AND MONITORING COMMITTEES

2010 – 2012 Member, TaiMed Biologics DSMB member for A Phase 1, Randomized, Double-Blinded, Placebo-

Controlled, Sequential Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics and

Pharmacodynamics of Subcutaneously Administered Ibalizumab in HIV-Negative, At-Risk Volunteers

2009 – present Member, Pan American Cancer Trials Network's Data and Safety Monitoring Board.

2010 – present Member, Obesity & Asthma: Genetics and Nutrigenetic Response to Omega-3 Fatty

Acids DSMB (Mayo Clinic)

2010 – present Member, NHLBI Blood and Marrow Transplant Clinical Trials Network, Data Safety and

Monitoring Board, Panel 2

ELIZABETH GARRETT-MAYER PAGE 4 OF 31 MAY 16

2010 – present Member, AIDS Malignancies Consortium, Data Safety and Monitoring Board

2014 – present Member, ANCHOR (Anal Cancer/HSIL Outcomes Research Study) Data Safety and Monitory Board

2015 – present Member, A Phase I/II Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of XXX in

Combination with nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer, Data

Safety and Monitoring Board.

EXTRAMURAL GRANTS/AWARD AMOUNT (CURRENT AND PAST): CURRENT RESEARCH SUPPORT 1P01CA186866-01A1 (NIH/NCI) PI: Li, Zihai 07/01/2015 – 06/30/2020

Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy

Role: Core Co-Leader

R01DA021619-05 (NIH/NIDA) PI: Carpenter 09/15/2013 – 05/31/2018

Brief, Novel Smoking Cessation in Primary Care: A Comparative Effectiveness Trial

Role: Co-Investigator

1 R01 NR012432-01A1(NIH/NINR) PI: Spruill 04/01/2012 - 01/31/2016

Ethno-Cultural Barriers to Health Literacy/Disease Management in AAs

Role: Co-Investigator

2P30 CA138313-01 (NIH/NCI) PI: Alberg/Garrett-Mayer 04/01/2008 – 03/31/2018

Medical University of South Carolina – Cancer Center Support Grant, Biostatistics Core

Role: Principal Investigator of Biostatistics Shared Resource R01CA154992-01 (NIH/NCI) PI: Carpenter 12/01/2010 – 3/31/2016

A Novel Trial of Smokeless Tobacco for Cessation Induction in Unmotivated Smokers Role: Co-Investigator 1 P01 CA154778-01A1 (Loyola/NIH/NCI) PI: Nishimura/Garrett-Mayer 09/01/2011 – 08/31/2016

TCR Gene Modified T Cells for Adoptive Immunotherapy

Role: Principal Investigator of Biostatistics Core 1 K12CA157688-01A1 (NIH/NCI) PI: Lilly 04/01/2013 – 03/31/2018

MUSC/HCC Paul Calabresi Clinical and Translational Oncology Training Program

Role: Co-Investigator R21CA194469-01 (NIH/NCI) PI: Turner 05/06/2015 – 04/30/2016 (PQ3) Ages and Race Specific Tumor Immune Response in Prostate Cancer Role: Co-Investigator COMPLETED RESEARCH SUPPORT

VA Merit Award PI: Gattoni-Celli 01/01/2010 - 12/31/2015

Vitamin D Supplementation in Veterans with Early-Stage Prostate Cancer: A Randomized Study

Role: Co-Investigator

R21CA158530 (NIH/NCI) PI: Reed 09/01/2012 – 08/31/2014

RCT of an Herbal Mouthrinse for Radiotherapy Induced Mucositis in Cancer Patients

Role: Co-Investigator

Leidos Biomedical Research, Inc. PI: Garrett-Mayer 04/24/2012 – 09/30/2014

Biostatistical Services Supporting the NCI's US-Latin America Clinical Research Network (US-LACRN)

Department of Defense W811XWH-09-1-0300 PI: Kraft 05/01/2009 – 04/30/2013

The Mechanism of Action of Unique Small Molecules that Inhibit the Pim Protein Kinase Blocking Prostate Cancer Cell Growth

Role: Co-Investigator

R01 CA127905 (NIH/NCI) PI: Moussa 05/01/09 – 03/31/14

ELIZABETH GARRETT-MAYER PAGE 5 OF 31 MAY 16

Thromboxane Beta Receptors in Human Bladder Cancers

Role: Co-Investigator

2 P01 CA097132-06 (NIH/NCI) PI: Ogretmen/Hannun 08/01/08 - 7/31/13

Sphingolipids in Cancer Biology and Therapy: Project 4-Regulation of ER Stress by de Novo Ceramide Synthesis in Head and Neck

Cancer

Role: Co-Investigator

5 R01 FD003542-02 PI: Frankel 09/01/2009 – 08/21/2012

A Phase I/II Study of Intraventricular DepoCyt (Orphan Drug Designation 06-2348) in Patients with Recurrent Glioblastoma

Role: Co-Investigator

R01 CA142362-02 (NIH/NCI) PI: Parsons 01/01/10 – 12/31/12

Regulation of the Tumor Microenvironment by KSHV

Role: Co-Investigator

K23 DA020482 (NIH/NIDA) PI: Carpenter 09/30/07-08/31/11

Stimulus Control and Trajectories of Adolescent Smoking

Role: Co-Investigator

Genentech AVF44815 PI: Thomas 02/10/09 – 03/11/12

A Randomized Open-Lable Multi-Institutional Phase II study of the Combination of Bevacizumab and Erlotinib Compared to

Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)

Role: Co-Investigator

2R44CA126461-02 (NIH/NCI) Subaward PI: Nishimura 06/01/2010 - 07/31/2011

Clinical Vector for TCR Immunotherapy Targeted to Melanoma

Role: Co-Investigator

5 P01 CA078582 (NIH/NCI) PI: Watson 09/30/08 - 04/30/10

Role of Ets Genes in Transformation and Differentiation

Role: Co-Investigator 1R03CA137826-01A1 (NIH/NCI) PI: Cunningham 07/01/09 – 06/30/11 Age-Specific and Age-Standardized Breast Cancer Subtype Incidence and Disparities Role: Co-Investigator

SECTR grant (state funded) PI: Voelkel-Johnson 10/01/08 – 9/30/09

Use of Exfoliated Cells in Urine for Detection of Cancer and Prediction of Treatment susceptibility

Role: Co-Investigator

1RO3 CA128482-01 (NIH/NCI) PI: Carter 06/01/07 – 12/31/08

The Impact of Dragon Boat Racing on Cancer Survivorship

Role: Co-Investigator

RSG-07-004-01-CCE (American Cancer Society) PI: Emens 10/01/06 - 01/15/07

Manipulating Immunoregulatory Pathways to Maximize Breast cancer Vaccine Activity

Role: Co-investigator

0B2P50CA088843-06A1 (NIH/NCI) PI: Davidson/Parmigiani 09/30/06 - 01/15/07

1BBreast SPORE / Biostatistics Core

2BRole: Co-investigator

1R2CA123888-01 (NIH) PI: Altiok 07/01/06 - 01/15/07

Prediction and Assessment of Response to Targeted Therapy in Pancreatic Cancer

Role: Co-investigator

R01CA116554 (NIH/NCI) PI: Hidalgo 06/01/06 – 01/15/07

Individualized Treatment of Pancreatic Cancer

Role: Co-investigator

ELIZABETH GARRETT-MAYER PAGE 6 OF 31 MAY 16

1R21CA117125 (NIH/NCI) PI: Messersmith 06/01/06 – 01/15/07

Evaluation of Bay43-9006/Cetuximab in Colorectal Cancer

Role: Co-investigator

P30CA006973 (NIH/NCI) PI: Abeloff / Parmigiani 05/01/06 – 01/15/07

Regional Oncology Research Center: Bioinformatics

Role: Co-investigator

NCI/Avon Foundation Partnership for Progress PI: Wolff 01/01/06 – 01/15/07

DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Treatment of Metastatic Breast Cancer.

Role: Co-investigator

TAX 2501 (Aventis) PI: Eisenberger 10/01/05 – 01/15/07

Prostate Cancer Taxotere Study

Role: Co-investigator

R21CA109283 (NIH/NCI) PI: Hidalgo 07/01/05 – 01/15/07

Pharmacogenomics of Erlotnib

Role: Co-investigator

R21CA112919 (NIH/NCI) PI: Hidalgo 09/17/04 – 01/15/07

Pharmacodynamic-Guided Dose-Finding Study of Rapamycin in Adult Patients with

Solid Tumors

Role: Co-investigator

DMS0342111 (National Science Foundation) PI: Parmigiani 05/01/04 – 04/30/06

Multi-Study Genomic Data Analysis

Role: Co-investigator

R21CA108774 (NIH) PI: Levitsky 12/30/03 – 11/30/05

Cancer Vaccines in the Treatment of CML

Role: Co-investigator

304-2294 PI: Stearns 10/01/03 – 09/30/05

(Translational Breast Cancer Research Consortium)

The Contralateral Breast as a Model for Chemoprevention: Preliminary Evaluation of Factors of Sensitivity of Resistance to

Anastrozole

Role: Co-investigator

310-2011 (Aventis) PI: Garrett-Mayer 09/01/03 – 01/15/07

A Multicenter, Open-Label Phase II Trial of Adjuvant Taxotere in Patients with High

Risk of Relapse Following Prostatectomy

Role: Co-investigator

P30CA006973 (NIH/NCI) PI: Abeloff/Wolff 05/15/03 – 01/15/07

Regional Oncology Research Center: Phase I Study of Doxcetaxel/ST 1571 in Breast Cancer

Role: Co-investigator

R21CA957030-01A1 (NIH) PI: Zeiger 05/01/03 – 04/30/05

Microarray Analysis of Thyroid Neoplasms

Role: Co-investigator

P01CA 098252 (NIH) PI: Wu/Wang 12/01/02 – 11/30/03

SPORE in Cervical Cancer

Role: Co-investigator

P50CA096784 (NIH) PI: Sidransky/Goodman 10/01/02 – 9/30/04

SPORE in Head and Neck Cancers

ELIZABETH GARRETT-MAYER PAGE 7 OF 31 MAY 16

Role: Co-investigator

P50CA096888 (NIH) PI: Ambinder/Piantadosi 09/01/02 – 01/15/07

SPORE in Lymphoma Cancer

Role: Co-investigator

PAR-99-128 (NIH/NCI) PI: Newschaffer 07/01/02 – 08/14/02

Serum FAS and the Early Detection of Breast Cancer

Role: Co-investigator

P01CA070970 (NIH/NCI) PI: Civin/Piantadosi 04/01/02 – 01/15/07

Hematopoietic Stem Cells for Transplantation

Role: Co-investigator

PA-00-047 (NIH) PI: Flinn 01/01/02 – 12/31/03

Augmenting ADCC with Rituximab and LAK Cells

Role: Co-investigator

P30CA006973 (NIH/NCI) PI: Abeloff /Piantadosi 07/13/01 – 01/15/07

Regional Oncology Research Center: Biostatistics

Role: Co-investigator

TURPG-00-294-01-PBP (American Cancer Soc.) PI: Shankar 07/01/01 – 06/30/04

Fruits and Vegetables Intervention in DC Public Housing

Role: Co-investigator

5P30 CA06973-39S2 (NIH/NCI) PI: Zabora 05/01/01 – 04/30/02

Regional Oncology Research Center – A Program for Depression Among African American Cancer Survivors

Role: Co-investigator

DK-00-002 (NIDDK) PI: Germino 09/30/00 – 09/29/03

The Hopkins DK Center for the Analysis of Gene Expression

Role: Co-investigator

P50CA88843 (NIH/NCI) PI: Davidson/Parmigiani 09/01/00 – 09/29/06

Breast SPORE / Biostatistics Core

Role: Co-investigator

R03 CA88769-02 (NIH/NCI) PI: Zabora 08/23/00 – 06/30/02

Family Dynamics and Problem-Solving Education for Caregivers

Role: Co-investigator

R01 A141956-02 (NIH) PI: Semba 09/01/99 – 08/31/03

Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS

Role: Co-investigator

R01-HD32247 (NIH) PI: Semba 08/15/99 – 07/31/02

Micronutrients and Mother-to-Child Transmission of HIV

Role: Co-investigator

R01-MH56639 (NIMH) PI: Zeger 08/15/97 – 07/31/03

Statistics for Longitudinal Studies of Mental Health Services

Role: Co-investigator

5M01 RR0035-32 (NIH) PI: Saudek 12/01/96 – 11/30/02

General Clinical Research Center (GCRC)

Role: Co-investigator

T32-MH19901 (NIH/NIMH) PI: Liang 07/01/93 – 06/30/03

ELIZABETH GARRETT-MAYER PAGE 8 OF 31 MAY 16

Biostatistics Mental Health Psychiatry Training Program

Role: Trainee

N01-AG12122 (NIH/NIA) PI: Fried 07/01/91 – 02/28/01

Women’s Health and Aging Study

Role: Research Assistant

AWARDS, HONORS, MEMBERSHIP IN HONORARY SOCIETIES:

1994 Phi Beta Kappa, Bowdoin College Chapter

1994 Summa cum laude, Bowdoin College

1995-1999 Biostatistics Mental Health/Psychiatry Training Grant

1998 Helen Abbey Award for Excellence in Student Teaching

2000 – present Delta Omega Society

2006 – present Associate Editor, Clinical Trials

2010 Hollings Cancer Center Cancer Prevention and Control Collaborative Paper Award

2014 Outstanding Mentor Award, Department of Public Health Sciences.

2016 MUSC Foundation Teaching Excellence Award Nominee

ACADEMIC COMMITTEE ACTIVITIES:

MUSC

2007 – 2008 Oncology Biostatistics Search Committee, Hollings Cancer Center and Department of Biostatistics & Epidemiology

2007 – 2009 Student Recruiting Committee , Department of Biostatistics & Epidemiology

2007 – 2009 Faculty Awards Committee , Department of Biostatistics & Epidemiology

2007 – 2009 Advanced Exam Committee, Department of Biostatistics & Epidemiology

2007 – 2009 Seminar Committee , Department of Biostatistics and Epidemiology

2007 – present Protocol Review Committee, Hollings Cancer Center

2007 – 2014 Co-chair, Data Safety Monitoring Committee, Hollings Cancer Center

2007 – present Member, Data Safety Monitoring Committee, Hollings Cancer Center

2007 – 2010 Executive Council, Hollings Cancer Center

2009 – 2011 Co-Director, Graduate Training Program, Biostatistics & Epidemiology, Department of Medicine

2009 – 2013 Senior Search Committee, Biostatistics & Epidemiology, Department of Medicine

2010 – present Medical Scientist Training Program (MD/PhDAdmissions Committee, College of Medicine

2011 Judge, Student Research Day, College of Graduate Studies

2011 – 2015 Chair, Admissions Committee, Department of Public Heath Sciences

2012 – 2014 Member, Search Committee for Dean of College of Graduate Studies

2013 – 2014 Member, Search Committee for Bioinformatics Candidates, Center for Genomics

2014 – present Member, Biostatistics Curriculum Committee, Department of Public Health Sciences

2015 – present Chair, Biostatistics Curriculum Committee, Department of Public Health Sciences

2015 – present Member, Masters of Public Health Program Committee, Department of Public Health Sciences

Johns Hopkins University

1999-2001 General Clinical Research Center, School of Medicine

2000-2005 Expressionist Working Group member, Schools of Medicine and Public Health

2000-2006 Oncology Scientific Clinical Review Committee, Sidney Kimmel Comprehensive Cancer Center

2004 Bioinformatics Faculty Search Committee, Departments of Oncology and Biostatistics

2004-2005 Co-Chair, Oncology Scientific Clinical Review Committee, Sidney Kimmel Comprehensive

Cancer Center

2006-2007 Chair, Oncology Clinical Research Review Committee, Sidney Kimmel Comprehensive Cancer

Center

2005-2007 Organizer, Cancer Clinical Trials Working Group, Sidney Kimmel Comprehensive Cancer Center

MAJOR TEACHING RESPONSIBILITIES:

COURSES TAUGHT:

MUSC

ELIZABETH GARRETT-MAYER PAGE 9 OF 31 MAY 16

Analysis of Survival Data 2008 Instructor (3 credit hours)

Department of Biostatistics, Bioinformatics, and Epidemiology

This is a one-semester introductory course in theory and application of analytic methods for time-to-event data. The methods covered

include nonparametric, parametric, and semi-parametric (Cox model) approaches. The topics covered will also include types of

censoring and truncation, sample size and power estimation, and a brief introduction to counting process method.

Biostatistical Methods II: Regression 2009-2010 Instructor (4 credit hours)

This is a one-semester course intended for graduate students pursuing degrees in biostatistics and related fields such as epidemiology

and bioinformatics. Topics covered will include linear, logistic, poisson, and Cox regression. Advanced topics will be included, such

as ridge regression or hierarchical linear regression if time permits. Estimation, interpretation, and diagnostic approaches will be

discussed. Software instruction will be provided in class in R and Stata.

Computing for Research I 2011-2014 Instructor (3 credit hours)

Students learn to use the primary statistical software packages for data manipulation and analysis, including (but not limited to): R, R

Bioconductor, SAS, SAS macro, and Stata. Additionally, students will learn: how to use the division's high speed cluster-computing

environment, how to practice the principles of reproducible research using Sweave in R, and how to use LaTeX and BibTeX for

manuscript and presentation development. This is a three credit course.

Introduction to Biostatistics: Methods I 2015 Instructor (4 credit hours)

This course introduces basic applied descriptive and inferential statistics. Topics include elementary probability concepts, an

introduction to statistical distributions, point and interval estimation, hypothesis testing, and simple linear regression and correlation.

Basic data management and analysis techniques will be introduced using computing software in a 1 hour computer lab session each

week.

Johns Hopkins University

Methods in Clinical Research 1991-2001 Instructor

The Johns Hopkins University School of Medicine. Two-week intensive course taught primarily to medical fellows and junior

faculty. Dr. Garrett-Mayer’s instruction included daily hour-long lectures using statistical software.

Statistical Reasoning in Public Health I & II 2000-2001 Instructor

Summer Epidemiology Institute, Johns Hopkins School of Hygiene and Public Health. Two-week intensive course taught to graduate

students. Dr. Garrett-Mayer’s instruction included daily 4 hour-long lectures and instructional labs on introductory biostatistics.

Statistics for Psychosocial Research: 2000-2004, 2006 Co-Instructor

Measurement and Structural Equation Models

The Johns Hopkins University Bloomberg School of Public Health. One semester (16 weeks). Dr. Garrett-Mayer has co-instructed

this course for five years with Dr. Richard Miech from the Department of Mental Health in the School of Public Health. Course

consists of three hours of lectures and one hour-and-a-half computer laboratory seesion per week. Nominated for “Golden Apple”

teaching award in 2000-2001 academic year.

Repeated Multi-Item Reponses in Clinical Trials 2001 Instructor

Biometrics Department, Ortho-McNeil Pharmaceuticals, Raritan, New Jersey. One-day short course. Conducted with three other

faculty from the Biostatistics Department at the School of Public Health. Dr. Garrett-Mayer’s component consisted of a two-hour

lecture on using latent class modeling for assessing treatment effects.

The Psychiatry Research Lecture Series 2001 Instructor

Psychiatry Research Center, Kennedy Krieger Institute, Baltimore, MD. Six-lecture series in basic statistical methods. One-hour

lectures given to psychiatrists and other faculty in psychiatric research from the Kennedy Krieger Institute.

Clinical Trials in 20 Hours 2002 Co-Instructor

Sidney Kimmel Cancer Center, Johns Hopkins University. Co-taught with four other faculty of the Oncology Center’s Division of

Clinical Trials and Biometry. Course consists of 20 one-hour lectures on statistical topics relevant to clinical trial design, conduct, and

analysis.

ST. GEORGE’S UNIVERSITY SCHOOL OF MEDICINE

ELIZABETH GARRETT-MAYER PAGE 10 OF 31 MAY 16

Biostatistics 2004 Instructor

St. George’s University School of Medicine, St. George, Grenada. Two-week intensive course taught to second-year medical students

in January and again in May. Dr. Garrett-Mayer’s instruction included daily two hour-long lectures biostatistics in medical research

and daily office hours.

MENTORING (PRE- AND POST-DOCTORAL)

MENTORING FROM 2000-2006 OCCURRED AT JOHNS HOPKINS UNIVERSITY.

MENTORING FROM 2007-PRESENT OCCURRED AT MEDICAL UNIVERSITY OF SOUTH CAROLINA

ADVISEES (AS PRIMARY ADVISOR)

2004-2008 Shu-Chih Su PhD, Biostatistics

2004 Naomi Ko MPH, Biostatistics

2004-2006 Lei Zhang ScM, Biostatistics

2005-2006 Yi-Chun Ou Yang ScM, Biostatistics

2007-2009 Emily Van Meter MS, Biostatistics

2007-2009 Chengwu Yang PhD, Biostatistics

2009-2010 Emily Van Meter PhD, Biostatistics

2011-2014 Codruta Chiuzan PhD, Biostatistics

2013-present Wei Wei PhD, Biostatistics

2014-present Nathaniel O’Connell PhD, Biostatistics

THESIS COMMITTEES

UNAME U UTITLE U UDEFENSE DATE U

Thomas Travison PhD, Biostatistics March 2002

Chiung-Yu Huang PhD, Biostatistics March 2002

Chuan-Yu Chen PhD, Mental Health January 2003

Yingyao Hu PhD, Economics (A&S) March 2003

Kathleen Hayden PhD, Mental Health August 2003

Wesley Eddings PhD, Biostatistics December 2003

Claire Lucas PhD, Health Policy &Mgmt December 2003

Kerry Pisacane PhD, Health Policy & Mgmt March 2004

Ya-Fen Chan PhD, Mental Health March 2004

Judith Bass PhD, Mental Health July 2004

Kathleen Cardona PhD, Population & Family Health Sciences March 2005

Christine Koth PhD, Mental Health August 2005

Michelle Kittleson PhD, Clinical Investigation (SOM) December 2005

Hong-fei Guo PhD, Biostatistics March 2006

Wei Hua PhD, International Health August 2006

Chengwu Yang PhD, Biostatistics August 2009

Jill Nonemaker MS, Epidemiology April 2008

Emily Van Meter PhD, Biostatistics August 2010

Jill Nonemaker MS, Epidemiology July 2007

James Whittle MSCR

Lee Wheless MSCR December 2008

Keisuke Shirai MSCR April 2009

Lee Wheless PhD, Epidemiology June 2012

Sarah Logan PhD, Epidemiology July 2013

Jessica Thaxton MSCR July 2014

Alice Mims MSCR July 2015

Rachel Moss Carroll PhD, Biostatistics November 2015

Melanie Jefferson PhD, Health & Rehabilitation Science April 2016

Matthew Hale PhD, Marine Science

David Neskey MSCR April 2016

THESIS PROPOSAL ORAL EXAM COMMITTEES

UNAME U UTITLE U UDEFENSE DATE

ELIZABETH GARRETT-MAYER PAGE 11 OF 31 MAY 16

Hong-fei Guo PhD, Biostatistics November 2001

Laura Pritchett PhD, Population & Family Health Sciences February 2002

Kathleen Hayden PhD, Mental Health November 2002

Michelle Shardell PhD, Biostatistics December 2002

Dongmei Liu PhD, Biostatistics December 2002

Xianghua Luo PhD, Biostatistics January 2003

Kerry Pisacane PhD, Health Policy & Management February 2003

David Cohen PhD, Biostatistics February 2003

Judith Bass PhD, Mental Health September 2003

Andrea Stone PhD, Mental Health March 2003

Ya-Fen Chan PhD, Mental Health March 2003

Yi Huang PhD, Biostatistics April 2003

Yandong Qiang PhD, International Health April 2003

Ting Wing PhD, Epidemiology May 2003

Jose Arbelaez PhD, Epidemiology May 2003

Jeanhee Hong PhD, Health Policy & Management June 2003

Wei Hua PhD, International Health July 2003

Michelle Chervak PhD, Health Policy & Management August 2003

Stephanie Smith PhD, Health Policy & Management August 2003

Christine Koth PhD, Mental Health September 2003

Brian Egleston PhD, Biostatistics November 2003

Erin Winstanley PhD, PhD, Mental Hygiene December 2003

Alyson Hall PhD, Health Policy & Management December 2003

Gwendolyn Bergen PhD, Health Policy & Management February 2004

Melissa Davey PhD, Mental Health June 2004

Michelle Kittelson PhD, GTPCI June 2004

Celeste Torio PhD, Health Policy & Management June 2004

Regina Shih PhD, Mental Health September 2004

Joseph Logan PhD, Health Policy & Management November 2004

Rajeeve Ramchand PhD, Mental Health December 2004

Robert Scharpf PhD, Biostatistics December 2004

Richard Skolasky PhD, Health Policy & Management February 2005

Shu-Chih Su PhD, Biostatistics October 2005

Amanda Kalaydjian PhD, Mental Health November 2005

Jessica Langbaum PhD, Mental Health January 2006

Haejoo Chung PhD, Health Policy & Management February 2006

Barbara Biedrzycki PhD, Nursing (SON) March 2006

Eva Bazant PhD, Population & Family Health Sciences May 2006

TRAINING GRANT PARTICIPATION

K23, Sean Berenholtz (Anesthesia and Critical Care Medicine, Johns Hopkins University)

K23, Wells Messersmith (Oncology, Johns Hopkins University)

K01, Hexin Chen (Oncology, Johns Hopkins University)

K23, Matthew Carpenter (Psychiatry and Cancer, Medical University of South Carolina)

Department of Defense Prostate Cancer Training Award. Thomas Beckham (PC101962) lab of James Norris). “Evaluation of

Acid Ceramidase Overexpression-Induced Activation of the Oncogenic Akt Pathway in Prostate Cancer.

K08, Co-Mentor for Yubin Kang (Division of Hematology/Oncology, Dept. of Medicine, MUSC). “Plerixafor for allogeneic

hematopoietic stem cell transplantation”

ACS Career Development Award, Katherine Sterba (Division of Biostatistics and Epidemiology, MUSC).

Conquer Cancer Foundation (ASCO) Career Development Award for Yubin Kang. (Division of Hematology/Oncology, Dept.

of Medicine, MUSC). A phase I/II study: enhancing donor cell recovery with CXCR4 antagonists

in hematopoietic cell transplantation

NCI K12 Paul Calabresi Career Development for Clinical & Translational Oncology Program Award

LECTURES AND PRESENTATIONS

MEETINGS/CONFERENCES/WORKSHOPS

AACR Cancer Biostatistics Workshop: Developing Targeted Agents

ELIZABETH GARRETT-MAYER PAGE 12 OF 31 MAY 16

Research Workshop, Sonoma, CA. July 2008 Instructor

A one-week intensive workshop in statistical methods in oncology and collaborative interactions between biostatisticians and

oncologists for entry-level to mid-level biostatisticians in the cancer field. Dr. Garrett-Mayer’s role is as a consulting

statisticians including daily group and one-on-one meetings with students, and informal teaching sessions. Dr. Garrett-Mayer

also gives a one-hour lecture on Phase II clinical trials in oncology.

AACR/ASCO Methods in Clinical Cancer Research Workshop,Vail, CO.

August 2002-2007, 2011-2015 Instructor

August 2008-2010, Course Director & Instructor

One-week intensive course for post-doctoral fellows and junior faculty in oncology. Dr. Garrett-Mayer’s role is as consulting

statistician, including daily group and one-on-one meetings with students, and informal teaching sessions. Dr. Garrett-Mayer

also gives didactic lectures: Novel Phase II Clinical Trials and Statistical Considerations: From Hypothesis to Analytic Plan.

Systematic Analysis of Research Risks Workshop Retreat in Queenstown, MD January 11-13, 2009

The goal of this workshop is to develop and apply a method for categorizing and evaluating the risks of research procedures.

For this purpose, workshop discussions will aim 1) to delineate more fine-grained categories of research risk than currently

exist; 2) to specify important normative and practical implications of these risk categories (e.g. whether consent must be

required); 3) to determine how these categories of risk map on to existing risk classifications in current research regulations;

and 4) to reach consensus on which risk category common research interventions should be placed based on the available

empirical data about the risks they pose. The project will focus on research that has social value, but offers no prospect of

direct benefit to individual study participants.

ASCO-AACI Workshop on Best Practices in Cancer Clinical Trials in Alexandria, VA March 8, 2016

The overarching goal of the initiative is to promote practical solutions to meeting existing regulatory and administrative

requirements on research. Other project elements include the following: (1) Stakeholder Survey: The working group is

overseeing a survey of trial administrators, investigators, and research staff to identify the most pressing issues in cancer

clinical trials that could be addressed by the initiative and to gather data on use of existing tools. (2) Proceedings of the

Workshop: The working group will write a manuscript that summarizes the discussion and recommendations from the

workshop and publish it as a Special Article in the Journal of Clinical Oncology. (3) Dissemination: ASCO will use the 2016

ASCO Annual Meeting to highlight project findings. It will also develop practical resources and toolkits to aid in the

implementation of the best practices identified by the working group.

INTRAMURAL LECTURES AND PRESENTATIONS

Lecture Series for Hematology/Oncology Fellows, Pediatric Oncology Fellows and Radiation Oncology Residents on

Methods in Clinical Cancer Research. 8 lectures per term, given semi-annually. Spring 2012 & Spring 2014

Graphical Display of Data and Statistics for Basic Science Researchers. Apple Tree Educational Series Lecture. April 21,

2014.

INVITED TALKS

An Introduction to Biostatistics and Some New Findings on the Effects of Complications in a Surgical Population. Bowdoin

Science Symposium, Brunswick, Maine, October 1997.

Methods for Determining the Number of Categories of Functional Disability. The Gerontological Society of America Annual

Meeting, Philadelphia, PA. November 23, 1998

Defining Major Depression Via Latent Class Model Diagnosis. Biostatistics Grand Rounds, The Johns Hopkins University

Bloomberg School of Public Health, Baltimore, MD. December 3, 1999.

Methods for Evaluating a Latent Class Model for Depression. Eastern North American Region (ENAR) International

Biometrics Society Annual Meeting, Chicago, NC. March 26, 2000.

Assessing Estimability of Latent Class Models Using a Bayesian Estimation Approach. Eastern North American Region

(ENAR) International Biometrics Society Annual Meeting,Charlotte, NC. March 26, 2001.

ELIZABETH GARRETT-MAYER PAGE 13 OF 31 MAY 16

Latent Class Model Graphical Diagnostic Tools Using An MCMC Estimation Procedure. Society for Prevention Research

Annual Meeting, Seattle, WA. June 1, 2002.

A Statistical Framework for Expression-Based Molecular Classification. Joint Statistical Meetings of the American Statistical

Association, New York, NY. August 12, 2002.

Methods for Evaluating the Performance of Diagnostic Tests in the Absence of a “Gold-Standard:” A Latent Class Model

Approach. Brown University Seminar Series, Brown University Division of Biostatistics. Providence, RI.

December 9, 2002.

Statistical Issues in the Analysis of Patient Outcomes. Guest lecture in ‘Patient Outcomes and Quality of Health Care.’

Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health. April 2003.

Statistical Issues in Clinical Studies Using Laboratory Endpoints. American College of Surgeons Oncology Group Meeting,

Montreal, Canada. June 5, 2003. College of Surgeons Canada.

Methods for Evaluating the Performance of Diagnostic Tests in the Absence of a “Gold-Standard:” A Latent Class Model

Approach. CARMA Institute, Virginia Commonwealth University. March 5, 2004.

A Nested Unsupervised Approach to Identifying Novel Molecular Subtypes. 2nd Institute of Mathematics and International

Society for Bayesian Analysis, Joint Meeting, Bormio, Italy. January 12, 2005.

A Likelihood Based Approach fro Early Stopping in Phase II Cancer Clinical Trials. Society for Clinical Trials Annual

Meeting. Orlando, FL. May 21, 2006.

Protocol Development and Study Design. Patient Advocate Training Workshop Understanding Process: Supporting Change

to Improve Cooperative Group Research. Baltimore, MD. November 6, 2006.

A Likelihood Based Approach for Early Stopping in Phase II Cancer Clinical Trials. GlaxoSmithKline, Collegeville, PA.

December 2006.

A Likelihood Based Approach for Early Stopping in Phase II Cancer Clinical Trials. Eastern North American Region,

International Biometric Society. Atlanta, GA. March 14, 2007.

Putting the Novelty Back in Phase II Studies. AACR/ASCO Methods in Clinical Cancer Research Workshop. Vail, CO.

Aug 2007 and Aug 2008.

Efficient Likelihood Based Approaches for Phase II Cancer Clinical Trials. Memorial Sloan Kettering Cancer Center

Seminar Series, New York, NY. May 14, 2008.

The Continual Reasssessment Method. NCI/CTEP Investigational Drug Phase I Trial Design Conference. Rockville, MD.

July 8, 2008.

Overview of Standard Phase II Design Issues. Cancer Biostatistics Workshop: Developing Targeted Agents. Sonoma, CA.

July 13-19, 2008.

Statistical Considerations in Protocol Development: From Hypothesis to Analysis. Methods in Clinical Cancer Workshop.

Vail, CO. Aug 2009.

Early Stopping in Cancer Clinical Trials: A Likelihood Approach. Johns Hopkins University. Baltimore, MD. June 23,

2009.

The CRM for ordinal and multivariate outcomes. CRM Workshop. Memorial Sloan Kettering Cancer Center. New York,

NY. October 2, 2009.

The questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs. South Carolina

Chapter of The American Statistical Association Annual Meeting. Charleston, SC. December 4, 2009.

ELIZABETH GARRETT-MAYER PAGE 14 OF 31 MAY 16

Novel Trial Designs for Early Phase Drug Development. CNIO Frontiers Meeting "Molecular Cancer

Therapeutics". Madrid, Spain. March 8-10, 2010.

Early Stopping in Cancer Clinical Trials: A Likelihood Approach. Quantitative Science Seminar Series. Vanderbilt

University, Nashville, TN. April 9, 2010.

Early Stopping in Cancer Clinical Trials: A Likelihood Approach. Society for Clinical Trials Annual Meeting, Invited

Session. Baltimore, MD. May 17, 2010.

Frequentist, Bayesian and Likelihood Designs for a Phase II Cancer Trial with a Time-to-Event Endpoint:

Head to Head Comparison of Three Philosophies of Trial Design. Invited Session. Vancouver, BC. May 17, 2011.

Biostatistical Aspects of Rational Clinical Trial Designs, Workshop on Pancreatic Cancer. The Banbury Center, Coldspring

Harbor, NY. June 21, 2011.

Dose finding designs driven by immunotherapy outcomes. 2nd CRM Workshop. University of Paris, Paris, France.

September 15-16, 2011.

Incorporating Early Stopping Rules in Phase II Studies. American Association of Cancer Research Annual Meeting.

Chicago, IL. March 31, 2012.

Dose finding designs driven by immunotherapy outcomes with application to a metastatic melanoma phase I trial. Southern

Regional Council on Statistics Annual Meeting. Jekyll Island, GA. June 4-6, 2012.

Adaptive phase I design for immunologic outcomes with safety constraints in cancer immunotherapy clinical trials. Joint

Statistical Meetings of the American Statistical Association. Montreal, Canada. August 5, 2013.

Clinical trial endpoints: selection, analysis and interpretation. San Antonio Breast Cancer Symposium - Cancer Therapy and

Research Center at UT Health Science Center. San Antonio, TX. Dec10-14, 2013

Likelihoood Approaches for Trial Designs in Early Phase Oncology Clinical Trials. Seminar Series, Columbia University

Department of Biostatistics. New York City, NY. April 24, 2014.

New Challenges: Model-based Dose Finding in the Era of Targeted Agents. Symposium on Early Phase Dose Finding

Methodology. Universite Paris VI. Paris, France, April 15, 2015.

Large Phase I Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives; Panel Discussion.

Accelerating Anticancer Agent Development and Validation Workshop. Bethesda, MD. May 7, 2015.

Statistical Considerations for Large First-in-Human Trials. Expansion Cohorts Mini-Symposium. Office of Hematology &

Oncology Products. United States Food and Drug Administration. Silver Spring, MD. September 10, 2015

The Changing Landscape of Phase I Trials in Cancer: A Novel Designs for Immunotherapies in Cancer. The Division of

Biomedical Statistics and Informatics. The Mayo Clinic. Rochester, Minnesota. October 2, 2015

Statistical Considerations for Large Expansion Cohorts. Friends of Cancer/Center for Health Policy at Brookings Annual

Meeting. Washington, DC. November 17, 2015.

The Changing Face of Early Phase Studies in Oncology Therapeutics: Tensions in a New Era of Immunotherapies.

Department of Biostatistics. St Jude’s Children Research Hospital. Memphis, TN. Feb 26, 2016

Statistical Issues in Cancer Clinical Trials: Designing Your Trial for Success. Accelerating Anti-Cancer Agents

Development and Validation: Fundamentals Workshop. Bethesda, MD. May 2, 2016

OTHER ACADEMIC PROFESSIONAL ACTIVITIES

Ad hoc Advisory Committee, Mock Site Visit. University of Texas San Antonio Cancer Therapy and Research Center.

December 19, 2013.

EXTRAMURAL PROFESSIONAL ACTIVITIES:

ELIZABETH GARRETT-MAYER PAGE 15 OF 31 MAY 16

CONSULTANTSHIPS

1999-2001 General Clinical Research Center, Johns Hopkins University

2002-2006 Department of Clinical Bioethics, National Institutes of Health

2004, 2008-9 Bingham McCutchen LLP

2015 - 2016 Tactical Therapeutics

2015 – 2016 Okava Pharmasceuticals

PUBLICATIONS:

UPEER REVIEWED JOURNAL ARTICLESU: EL

Electronic access to journal articles is available by clicking on the links below, or by visiting My NCBI Bibliography .

1. Pronovost P, Jenckes MW, Dorman T, Garrett E, Breslow MJ, Rosenfeld BA, Lipsett PA, Bass E. Organizational

characteristics of intensive care units related to outcomes of abdominal aortic surgery. Journal of the American Medical

Association. 1999; 281:1310-1317. PMID: 10208147

2. Lyketsos CG, Garrett E, Liang KY, Anthony JC. Cannabis use and cognitive decline in persons under 65. American

Journal of Epidemiology. 1999; 149:794-800. PMID: 10221315

3. Pronovost PJ, Dorman T, Sadnivokoff N, Garrett E, Breslow MJ, Rosenfeld BA. The association between preoperative

patient characteristics and both clinical and economic outcomes after abdominal aortic surgery. Journal of Cardiothoracic

and Vascular Anesthesiology. 1999; 13:549-554. PMID: 10527223

4. Ahn NU, Sponseller PD, Ahn UM, Nallamshetty L, Rose PS, Buchowski JM, Garrett ES, Kuszyk BS, Fishman EK, and

Zinreich SJ. Dural ectasia in the marfan syndrome: mr and ct findings and criteria. Genetics in Medicine. 2000; 2 (3):173-

179. PMID: 11256662

5. Ahn UM, Ahn NU, Buchowski J, Garrett ES, Seiber A, Kostuik JP. Cauda equina syndrome secondary to lumbar disc

herniation: a meta-analysis of surgical outcomes. Spine. 2000; 25 (12):1515-1522. PMID: 10851100

6. Chaves PHM, Garrett ES, Fried LP. Screening for risk of mobility disability in the clinical setting: predictive nomograms

for older women. Archives of Internal Medicine. 2000; 160 (6):2525-2533. PMID: 10979066

7. Semba R, Garrett ES, Johnson B, Guralnik JM, Fried LP. Hypovitaminosis D Among women with and without disability.

American Journal of Clinical Nutrition. 2000; 72 (6):1529-1534. PMID: 11101482

8. Garrett ES, Zeger SL. Latent class model diagnosis. Biometrics. 2000; 56 (4):1055-1067. PMID: 11129461

9. Ling SM, Fried LP, Garrett ES, Hirsch R, Guralnik JM, Hochberg MC, and the Women’s Health and Aging

Collaborative Research Group. The Accuracy of Self-Report of Physician Diagnosed Rheumatoid Arthritis in Moderately

to Severely Disabled Older Women. Journal of Rheumatology, 2000; 27(6): 1390-1394. PMID: 10852259

10. Ahn NU, Ahn UM, Nallamshetty L, Rose PS, Buchowski JM, Garrett ES, Kebaish, KM, Spononseller, PD. The lumbar

interpediculate distance is widened in adults with the marfan syndrome: data from 32 cases. Acta Orthopedica

Scandinavica. 2001; 72 (1); 67-71. PMID: 11327417

11. Hruban RH, Adsav NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G,

Longnecker DS, Luttges J, Offerhaus GJ. Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification

System for Pancreatic Duct Lesions. American Journal of Surgical Pathology. 2001; 25(5):579-586. PMID: 11342768

12. Huang W, Zeger SL, Anthony JC, Garrett ES. Latent variable model for joint analysis of multiple repeated and bivariate

time events. The Journal of the American Statistical Association. 2001; 96: 906-914.

13. Nussenblatt V, Mukasa G, Metzger A, Ndeezi G, Garrett E, Semba RD. Anemia and interleukin-10, tumor necrosis

factor-a, and erythropoietin among children with acute, uncomplicated plasmodium falciparum malaria. Clinical and

Diagnostic Laboratory Immunology. 2001; 8:1164-1170. PMCID: PMC96244PMID: 11687458

ELIZABETH GARRETT-MAYER PAGE 16 OF 31 MAY 16

14. Semba RD, Kumwenda N, Taha TE, Mtimavalye L, Broadhead R, Garrett E. Impact of vitamin a supplementation on

anaemia and plasma erythropoietin concentrations in pregnant women: a controlled clinical trial. European Journal of

Haemotlogy. 2001; 66:389-395. PMID: 11488938

15. Melikian G, Mmiro F., Ndugwa C, Perry R, Jackson JB, Garrett E. Relation of Vitamin a and carotenoid status to growth

failure and mortality among ugandan infants with human immunodeficiency virus. Nutrition. 2001; 17 (7-8):567-572.

PMID: 11448574

16. Pronovost P, Garrett ES, Dorman T, Jenckes MW, Breslow M, Bass E. Variation in complications and opportunities for

improvement in quality of care of patients having abdominal aortic surgery. Langenbeck’s Archives of Surgery. 2002; 386

(4):249-256. PMID: 11466565

17. Pronovost PJ, Dang D, Dorman T, Lipsett PA, Garrett ES, Jenckes M. Intensive care unit nurse staffing associated with

increased risk of complications after abdominal aortic surgery. Effective Clinical Practice. 2001; 4(5): 199-206. PMID:

11685977

18. Levis M, Tse K-F, Smith BD, Garrett E, Small D. A flt3 tyrosine kinase inhibitor is selectively cytotoxic to aml blasts

harboring flt3/itd mutations (brief report). Blood. 2001; 98(3): 885-887. PMID: 11468194

19. Ahn NU, Ahn UM, Nallamshetty L, Springer BD, Buchowski JM, Funches L, Garrett ES, Kostuik JP, Kebaish KM,

Sponseller PD. Cauda equina syndrome in ankylosing spondylitis (the CES-AS syndrome): meta-analysis of outcomes

after medical and surgical treatments. Journal of Spinal Disorders. 2001; 14(5):427-433. PMID: 11586143

20. Ahn NU, Nallamshetty L, Ahn UM, Buchowski JM, Rose PS, Garrett ES, Kebaish KM, Sponseller PD. Dural ectasia

and conventional radiography in the marfan lumbosacral spine. Skeletal Radiology. 2001; 30(6):67-71. PMID: 11465775

21. Munter P, Garrett E, Klag M, Coresh J. Trends in stroke prevalence between 1973 and 1991 in the united states

population 25-74 years of age. Stroke. 2001; 33(5): 1209-1213. PMID: 11988592

22. Berenholtz SM, Pronovost PJ, Mullany D, Garrett E, Ness P, Dorman T, Klag M. Predictors of transfusion for spine

surgery in Maryland, 1997-2000. Transfusion. 2002; 42(4): 183-189. PMID: 11896333

23. Eichler FS, Itoh R, Barker PB, Mori S, Garrett ES, van Zijl P, Moser HW, Raymond GV. Proton mr spectroscopic and

diffusion tensor brain mr imaging in x-linked adrenoleukodystrophy: initial experience. Radiology. 2002; 225(1):245-252.

PMID: 12355012

24. Giardiello FM, Hylind LM, Yang VW, Krush AJ, Petersen GM, Brensinger JD, Piantadosi S, Garrett ES, Offerhaus GJA,

and Hamilton SR. Primary Chemoprevention in Familial Adenomatous Polyposis. N Engl J Med. 2002; 346:1054-9.

PMCID: PMC2225537; PMID: 11932472

25. Garrett ES, Eaton WW, Zeger SL. Methods for evaluating the performance of diagnostic tests in the absence of a gold

standard: a latent class model approach. Stat Med. 2002; 21(9) 1289-1307. PMID: 12111879

26. Emens LA, Kennedy MJ, Fetting JH, Davidson NE, Elza-Brown K, Garrett ES, Armstrong DA. A phase I toxicity and

feasibility trial of sequential dose dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed

by high dose consolidation for high risk primary breast cancer. Breast Cancer Research and Treatment. 2002; 76(2): 145-

156. PMID: 12452452

27. Parmigiani G, Garrett E, Anbazhagan R, Gabrielson E. A Statistical framework for expression-based molecular

classification in cancer. Journal of the Royal Statistical Society, Series B, with discussion. 2002; 64:717-736.

28. Nilsson KR, Berenholtz SM, Dorman T, Garrett E, Kaufman HS, Pronovost PJ. Preoperative predictors of blood

transfusion in colorectal cancer surgery. Journal of Gastrointestinal Surgery. 2002; 6(5): 753-762. PMID: 12399066

29. Tanavde VM, Malehorn MT, Lumkul R, Gao Z,Wingard J, Garrett ES, Civin CI. Human stem-progenitor cells from

neonatal cord blood have greater hematopoietic expansion capacity than those from mobilized adult blood. Experimental

Hematology. 2002; 7(2):816-823. PMID: 12135681

ELIZABETH GARRETT-MAYER PAGE 17 OF 31 MAY 16

30. Yoon DS,Wersto RP, ZhouW, Chrest FJ, Garrett ES, Kwon TK, Gabrielson ES. Variable levels of chromosomal

instability and mitotic spindle checkpoint defects in breast cancer. American Journal of Pathology. 2002; 161: 391-397.

PMCID: PMC1850727; PMID: 12163363

31. Fujii H, Anbazhagen R, Bornman DM, Garrett ES, Perlman E, Gabrielson E. Mucinous cancers have fewer genomic

alterations than more common classes of breast cancer. Breast Cancer Research and Treatment. 2002; 76(3): 255-260.

PMID: 12462386

32. Nallamshetty L, Ahn NU, Ahn UM, Buchowski JM, An HS, Rose PS, Garrett ES, Erkula G, Kebaish KM, Sponseller PD.

Plain radiography of the lumbosacral spine in Marfan syndrome. Spine Journal. 2002; 2(5):327-33. PMID: 14589463

33. Ling, S.M., Fried, L.P, Garrett, E.S., Fan, M.Y., Rantanen, T., Bathon, J.M. Knee osteoarthritis compromises early

mobility function: the women's health and aging study II. The Journal of Rheumatology. 2003; 30(1): 114-120. PMID:

12508399

34. Morrison W, Haas E, Shaffner D, Garrett E, Fackler J. Noise, stress and annoyance in a pediatric intensive care unit.

Critical Care Medicine, 2003; 31(1): 113-199. PMID: 12545003

35. Scharpf R, Garrett ES, Hu J, Parmigiani G. Statistical Modeling and Visualization of Molecular Profiles in Cancer.

Biotechniques. 2003; 34: S22-S29. PMID: 12664681

36. Kominsky S, Argani P, Evron E, Korz D, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi O, Sukumar S. Loss of

tight junction protein claudin-7 correlates with histologicl grade in both ductal carcinoma in situ and invasive ductal

carcinoma of the breast. Oncogene. 2003; 22(13): 2021-2033. PMID: 12673207

37. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H., Christensen SB, Isaacs J. Prostate-specfic

antigen (psa) activated thapsigargin in prodrug as targeted therapy for prostate cancer. Journal of the National Cancer

Institute. 2003; 95(13): 990-1000. PMID: 12837835

38. Kozlow J, Berenholtz S, Garrett E, Dorman T, Pronovost P. Epidemiology and impact of aspiration preumonia in patients

undergoing surgery in maryland 1999 - 2000. Critical Care Medicine. 2003;31(7): 1930-1937. PMID: 12847385

39. Derr R, Garrett ES, Stacey GA, Saudek CD. Is hemoglobin a1c affected by glycemic instability? Diabetes Care. 2003;

26(10): 2728-2733. PMID: 14514571

40. Wolpoe ME, Lutz ER, Ercolini AM, Murata S, Ivie SE, Garrett ES, Emens LA, Jaffee EM, Reilly RT. HER-2/neu-

specific monoclonal antibodies collaborate with HER-2/neu-targeted granucolyte macrophage colony-stimulating factor

secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in HER- 2/neu-

transgenic mice. The Journal of Immunology. 2003; 171: 2161-2169. PMID: 12902523

41. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrota J, Polyak C, Sukumar S, Argani P. DNA methylation of Rassf1a,

Hin-1, Rar-, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. International Journal of Cancer. 2003;

107: 970-975. PMID: 14601057

42. Handa VL, Garrett ES, Hendrix S, Yasmeen S, Gold E, Robbins J. Progression and remission of pelvic organ prolapse: a

longitudinal study of menopausalwomen. American Journal of Obstetrics and Gynecology. 2004; 190: 27-32, 2004.

PMID: 14749630

43. Parmigiani G, Garrett ES, Anbazhagan R, Gabrielson E. The molecular classification of lung cancer: a cross-study

comparison of gene expression data sets. Chest. 2004 May; 125(5 Suppl):103S. PMID: 15131026

44. Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T, Garrett

ES, Parmigiani G, Broome C, Sukumar S. ER/PR-negative breast cancers of young african american women have a higher

frequency of methylation of multiple genes than those of caucasian women. Clinical Cancer Research. 2004; 10(6): 2052-

2057. PMID: 15041725

45. Mehrotra J, Vali M, McVeigh M, Kominsky SL, Fackler, MJ, Lahti-Domenici J, Polyak K, Sacchi N, Garrett-Mayer E,

Argani P, Sukumar S. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and

lung. Clinical Cancer Research. 2004; 10(9): 3104-3109. PMID: 15131050

ELIZABETH GARRETT-MAYER PAGE 18 OF 31 MAY 16

46. Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES, Shah KV, Gillison ML. Oral human papillomavirus

infection in adults is associated with sexual behavior and HIV serostatus. Journal of Infectious Disease. 2004; 189(4):

686-698. PMID: 14767823

47. Rudek MA, Sparreboom A, Garrett ES, Gianni L, Vigano L, Armstrong DK,Wolff AC, Verweij J, Baker SD. Factors

affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. European Journal of Cancer.

2004; 40: 1170-1178. PMID: 15110880

48. Masayesva B, Ha P, Garrett-Mayer E, Pilkington T, Mao R, Pevsner J, Speed T, Benoit N, Moon CS, Sidransky D,

Westra W, Califano J. Gene expression alterations over large chromosomal regions in cancers includes multiple genes

unrelated to malignant progression. Proceedings of the National Academy of Sciences. 2004; 101(23): 8715-8720.

PMCID: PMC423261; PMID: 15155901

49. Cope L, Zhong X, Garrett E, Parmigiani G. MergeMaid: R Tools for Merging and Cross-Study Validation of Gene

Expression Data. Statistical Applications in Genetics and Biology. 2004; 3(1): Article 29. PMID: 16646808

50. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural History of Paroxysmal Nocturnal Haemoglobinuria using

modern diagnostic assays. British Journal of Haematology. 2004; 26(1): 133-138. PMID: 15198744

51. Kwiterovich PO, Virgil DG, Garrett ES, Otvos J, Driggers R, Blakemore K, Cockrill S, Macfarlane RD. Lipoprotein

heterogeneity at birth: influence of gestational age and race on lipoprotein subclasses and lp(a) lipoprotein. Ethnicity and

Disease. 2004; 14(3): 351-359. PMID: 15328936

52. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Garrett-Mayer E, Argani P, Sukumar S. Quantitative multiplex

methylation-specific PCR assay for the detection of promoter methylation in multiple genes in breast cancer. Cancer

Research. 2004; 64(13):4442-4452. PMID: 15231653

53. Kasamon YL, Jones RJ, Diehl LF, Borowitz MJ, Garrett-Mayer E, Ambinder RF, Abrams RF, Zhang Z, Flinn IW.

Outcomes of Autologous and Allogeneic Blood or Marrow Transplantation for Mantle Cell Lymphoma. Biology of Blood

and MarrowTransplantation. 2004; 11: 39-46. PMID: 15625543

54. Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, Herman JG, Gabrielson E. Hypermethylation in

histologically distinct classes of breast cancer. Clinical Cancer Research. 2004; 10: 5998-6005. PMID: 15447983

55. Gitlin J, Cook LL, Linton OW, Garrett-Mayer E. Comparison of ‘ ‘B” Readers’ Interpretations of Chest Radiographs for

Asbestos Related Changes. Academic Radiology. 2004; 11: 843-856. PMID: 15354304

56. Hurst SA, Teagarden JR, Garrett E, Emanuel EJ. Conserving Scarce Resources: Willingness of Health Insurance

Enrollees to Choose Cheaper Options. Journal of Law, Medicine, and Ethics. 2004; 32: 496-499. PMID: 15490596

57. Berenholtz SM, Pronovost PJ, Lipsett PA, Hobson D, Earsing K, Farley JE, Milanovich S, Garrett-Mayer E, Winters BD,

Rubin HR, Dorman T, Perl TM. Eliminating Catheter-Related Bloodstream Infections in the Intensive Care Unit. Critical

Care Medicine. 2004; 32(10): 2014-2020. PMID: 15483409

58. Garrett ES, Parmigiani G. A nested unsupervised approach to identifying novel molecular subtypes. Bernoulli. 2004;

10(6): 951-956.

59. Keen JC, Garrett-Mayer E, Pettit C, Mack KM, Hermann JG, Davidson NE. Epigenetic regulation of protein phosphatase

2A (PP2A), lymphoactin (XCL1), and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer

Biology and Therapy. 2004; 3(12): 304-12. PMID: 15662126

60. Ulrich CM, Danis M, Koziol D, Garrett-Mayer E, Hubbard R, Grady C. Does it pay to pay? A randomized trial of

financial incentives in survey research. Nursing Research. 2005; 54(3):178-183. PMID: 15897793

61. Ravi R, Jain AJ, Schulick RD, Pham, Prouser TS, Allen H, Garrett-Mayer E, Yu H, Pardoll D, Ashkenazi A, Bedi A.

Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2

Ligand/TRAIL. Cancer Research. 2004; 64: 9105-9114. PMID: 16452233

ELIZABETH GARRETT-MAYER PAGE 19 OF 31 MAY 16

62. Friedman K, Somervell H, Patel P, Melton GB, Garrett-Mayer E, Dackiw AP, Civelek AC, Zeiger MA. Effect of

calcium channel blockers on the sensitivity of preoperative 99mTc-MIBI SPECT for hyperparathyroidism. Surgery. 2004;

136: 1199-1204.U PMID: 15657576

63. Chen H, Rubin E, Zhang H, Chung S, Jie CC, Garrett E, Biswal S, Sukumar S. Identification of transcriptional targets of

HOXA5. Journal of Biochemistry and Molecular Biology. 2005; 280(19):1973-1980. PMID: 15757903

64. Kwiterovich PO, Cockrill SL, Virgil DG, Garrett ES, Otvos J, Knight-Gibson C. An elevated large high-density

lipoprotein enriched in apolipoprotein C-I: A novel biochemical marker in infants of lower birth weight and younger

gestational age. Journal of the American Medical Association. 2005; 293(15): 1891-1899. PMID: 15840864

65. Pace C, Talisuna A, Wendler D, Maiso F, Wabwire-Mangen F, Bakyaita N, Okiria E, Garrett-Mayer ES, Emanuel E,

Grady C. Quality of parental consent in a Ugandan malaria study. American Journal of Public Health. 2005; 95(7):1184-

1189. PMCID: PMC1449338; PMID: 15933235

66. Kasamon YL, Byrd JC, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Flinn IW. Phase I study of

interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic

leukemia. Clinical Cancer Research. 2005;11(23):8413-8417.U PMID: 16322303

67. Diaz LA Jr, Cheong I, Foss CA, Zhang X, Peters BA, Agrawal N, Bettegowda C, Karim B, Liu G, Khan K, Huang X,

Kohli M, Dang LH, Hwang P, Vogelstein A, Garrett-Mayer E, Kobrin B, Pomper M, Zhou S, Kinzler KW, Vogelstein B,

Huso DL. Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicological Sciences. 2005; 88(2): 562-

575. PMID: 16162850

68. Stewart ZA, Blackford A, Somervell H, Friedman K, Garrett-Mayer E, Dackiw AP, Zeiger MA. 25-hydroxyvitamin D

deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally

invasive parathyroidectomy. Surgery. 2005;138(6): 1018-1025; discussion 1025-1026. PMID: 16360386

69. Allen E, Piontek KB, Garrett-Mayer E, Garcia-Gonzalez M, Gorelick KL, Germino GG. Loss of polycystin-1 or

polycystin–2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone

receptors. Human Molecular Genetics. 2006; 15(1):11-21.

70. Ravi R, Fuchs EJ, Jain A, Pham V, Yoshimura K, Prouse T, Jalla S, Zhou XZ, Garrett-Mayer E, Kaufmann SH, Schulick

RD, Pardoll DM, Bedi A. Resistance of Cancers to Immunologic Cytotoxicity and Adoptive Immunotherapy via XIAP

expression and co-existing defects in Mitochondrial Death Signaling. Cancer Research. 2006; 66(3): 1730-1739. PMID:

16452233

71. Garrett-Mayer, E. The Continual Reassessment Method for Dose-Finding: A Tutorial. Clinical Trials. 2006; 3(1): 57-

71. PMID: 16539090

72. Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar

S. Ductal access for prevention and therapy of mammary tumors. Cancer Research. 2006; 66(2):638-645. PMID:

16423990

73. Lo PK, Mehrotra J, D’Costa A, Fackler MJ, Garrett-Mayer E, Argani P, Sukumar S. Epigenetic Suppression of Secreted

Frizzled Related Protein 1 (SFRP1) Expression in Human Breast Cancer. Cancer Biology and Therapy. 2006 Mar 6; 5(3)

281-286.U PMID: 16410723

74. Landa R, Garrett-Mayer E. Development in Infants with Autism Spectrum Disorders: A Prospective Study. Journal of

Child Psychology and Psychiatry. 2006; 47(6):629-638. PMID: 16712640

75. Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM,

Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ. Graft-versus Host Reactions and the Effectiveness of Donor

Lymphocyte Infusions. Biological Blood Marrow Transplantation. 2006; 12(4):414-421. PMID: 16545725

76. Shalowitz DI, Garrett-Mayer E, Wendler D. The Accuracy of Surrogate Decision-Makers: A Systematic Review.

Archives of Internal Medicine (Review). 2006; 166(5):493-497. PMID: 16534034

77. Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson NE, Khan

ELIZABETH GARRETT-MAYER PAGE 20 OF 31 MAY 16

SA, Sukumar S. Quantitative Multiplex-Methylation Specific PCR Analysis Doubles Detection of Tumor Cells in Breast

Ductal Fluid. Clinical Cancer Research. 2006 Jun 1; 12(11 Pt 1): 3306-3310. PMID: 16740751

78. Shankar S, Klassen AC, Garrett-Mayer E, Houts PS, Wang T, McCarthy M, Cain R, Zhang L. Evaluation of a nutrition

education intervention for women residents of Washington, DC, public housing communities. Health Educ Res. 2007

Jun;22(3):425-37. PMID: 16982649

79. Hurst SA, Slowther AM, Forde R, Pegoraro R, Reiter-Theil S, Perrier A, Garrett-Mayer E, Danis M. Prevalence and

determinants of physician bedside rationing: data from Europe. Journal of General Archives of Internal Medicine. 2006

Nov: 21 (11): 1138-1143. PMCID: PMC1831659; PMID: 16836629

80. Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and

allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin’s lymphoma. Biol Blood Marrow

Transplant. 2006 Sep; 12(9): 965-972. PMID: 16920563

81. Hurst S., Perrier A., Pegoraro R., Reiter-Theil S., Forde R., Slowther A., Garrett-Mayer E., Danis M.: European

Physicians' Experience with Ethical Difficulties in Clinical Practice. Journal of Medical Ethics. 2007 Jan; 33(1): 51-57.

PMID: 17209113

82. Lancet, JE, Gojo I, Gotlibn J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH,

Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in

poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007 Feb 15; 109(4): 1387-

1394. PMCID: PMC1794070 PMID: 17082323

83. Ulrich CM, Danis M, Ratcliffe SJ, Garrett-Mayer E, Koziol D, Soeken KL, Grady C. Ethical conflict in nurse

practitioners and physician assistants in managed care. Nursing Research. 2006 Nov-Dec; 55(6):391-401. PMID:

17133146

84. Sullivan M, Finelli J, Marvin A, Garrett-Mayer E, Bauman M, Landa R. Response to joint attention in toddlers at risk for

austism spectrum disorder: a prospective study. J Autism Dev Disord. 2007 Jan; 37(1):37-48. PMID: 17216332

85. Nilsson KR, Berenholtz SM, Garrett-Mayer E, Dorman T, Klag MJ, Pronovost PJ. Association between venous

thromboembolism and perioperative allogeneic transfusion. Archives of Surgery. 2007 Feb; 142(2): 126-132. PMID:

17309963

86. Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA,

Deweese TL. Phase II Study of Imatinib Mesylate in Patients with Prostate Cancer with Evidence of Biochemical Relapse

After Definitive Radical Retropubic Prostatectomy or Radiotherapy. Urology. 2007 Mar;69(3):526-31. PMID: 17382158

87. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR.

A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007 Mar

7;99(5):376-85. PMID: 17341729

88. Shalowitz DI, Garrett-Mayer E, Wendler D. How Should Treatment Decisions Be Made for Incapacitated Patients, and

Why? PLoS Med. 2007 Mar 13;4(3):e35. PMCID: PMC1820603; PMID: 17388655

89. Jimeno A, Hallur G, Chan A, Zhang X, Cusatis G, Chan F, Shah P, Chen R, Hamel E, Garrett-Mayer E, Khan S, Hidalgo

M. Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein

tau is predictive of their activity in pancreatic cancer. Molecular Cancer Therapeutics. 2007 May;6(5):1509-16 PMID:

17483439

90. Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, Dipaola RS, Roth BJ, Cookson

MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger

MA. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional

pilot study. Journal of Urology. 2007 May;177(5):1777-81. PMID: 17437819

91. Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent

uterine leiomyosarcoma. Gynecol Oncol. 2007 Jul;106(1):82-8. PMID: 17434579

ELIZABETH GARRETT-MAYER PAGE 21 OF 31 MAY 16

92. Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E, Argani

P, Davidson NE, Talalay P, Kensler TW, Visvanathan K. Preclinical and Clinical Evaluation of Sulforaphane for

Chemoprevention in the Breast. Carcinogenesis. 2007 Jul;28(7):1485-90. PMID: 17347138

93. Lee JS, Lo PK, Fackler MJ, Argani P, Zhang Z, Garrett-Meyer E [sic], Sukumar S.A Comparative Study of Korean with

Caucasian Breast Cancer Reveals Frequency of Methylation in Multiple Genes Correlates with Breast Cancer in Young,

ER,PR-negative Breast Cancer in Korean Women. Cancer Biology Therapy 2007 Apr 23;6(7). PMID: 17611401

94. Landa RJ, Holman KC, Garrett-Mayer E. Social and communication development in toddlers with early and later

diagnosis of autism spectrum disorders. Archives of General Psychiatry. 2007 Jul;64(7):853-64. PMID: 17606819

95. Koyfman SA, Agrawal M, Garrett-Mayer E, Krohmal B, Wolf E, Emanuel EJ, Gross CP. Risks and benefits associated

with novel phase 1 oncology trial designs. Cancer. 2007 Sep 1;110(5):1115-24. PMID: 17628485

96. Lavely WC, Goetze S, Friedman KP, Leal JP, Zhang Z, Garret-Mayer E [sic], Dackiw AP, Tufano RP, Zeiger MA,

Ziessman HA. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi

parathyroid scintigraphy. Journal of Nuclear Medicine. 2007 Jul: 48(7): 1084-1089. PMID: 17574983

97. Armstrong AJ, Garrett-Mayer E, Ou Yang Y-C, Carducci MA, Tannock I, de Wit R, Eisenberger MA. Prostate-specific

antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. 2007

Sep; 25(25): 3965-3970. PMID: 17761981

98. Bolanos-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky

R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB. Induction of Autologous

Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma.

Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-1191. PMCID: PMC2271148; PMID: 17889355

99. Garrett-Mayer E, Parmigiani G, Zhong X, Cope L, Gabrielson E. Cross-study validation and combined analysis of gene

expression microarray data. Biostatistics,2008 Apr;9(2):333-54. PMID: 17873151

100. Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA. Survival in Men with Non-Metastatic Prostate

Cancer Treated with Hormone Therapy: A Quantitative Systematic Review. Journal of Clinical Oncology, 2007 Nov 1;

25(31): 4998-5008. PMID: 17971600

101. Armstrong AJ, Garrett-Mayer ES, Ou Yang YC, de Wit R, Tannock IF, Eisenberger MA. Contemporary Prognostic

Nomogram for Men With Hormone-Refractory Metastatic Prostate Cancer (HRPC): A TAX327 Study Analysis. Clinical

Cancer Research, 2007 Nov 1; 13(21): 6396-6403. PMID: 17975152

102. Klassen AC, Garrett-Mayer E, Houts PS, Shankar S, Torio CM. The relationship of body size to participation and

success in a fruits and vegetables intervention among low-income women. Journal of Community Health, 2008

Apr;33(2):78-89. PMID: 18074208

103. Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Phase I dose

escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC

Cancer, 2007 Dec 20; 7:231. PMCID: PMC2241632 PMID: 18096059

104. Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW,

Claybourne Q, Tokumaru Y, Lee J, Goldenberg D, Garrett-Mayer E, Goodman S, Moon CS, Koch W, Westra WH,

Sidransky D, Califano JA. Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis

Tool for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Reseach 2008 14: 97-107. PMID: 18172258

105. Hooker A, Ten Tije A, Carducci M, Weber J, Garrett-Mayer E, Gelderblom H, McGuire W, Verweij J, Karlsson M,

Baker S. Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function:

Incorporating Cytochrome P450 3A Activity Measurements. Molecular Therapeutics 2008 Jan 9. PMID: 18183036

106. Choti MA, Kaloma F, de Oliviera ML, Nour S, Garrett-Mayer ES, Sheth S, Pawlik TM Patient variability in

intraoperative ultrasonographic characteristics of colorectal liver metastases. Archives of Surgery 2008 Jan; 143(1): 29-34.

PMID: 18209150

ELIZABETH GARRETT-MAYER PAGE 22 OF 31 MAY 16

107. Warlick ED, O’Donnell PV, Borowitz M, Grupka N, Decloe L, Garrett-Mayer E, Borrello I, Brodsky RA, Fuchs EJ, Huff

CA, Luznik L, Matsui WH, Ambinder R, Jones RJ, Smith BD. Myeloablative allogeneic bone marrow transplant using T-

cell depleted allografts followed by post-transplant GM-CSF in high risk myelodysplastic syndromes. Leukemia Research,

2008 Sep;32(9):1439-47. PMID: 18261793

108. Abukhdeir AM, Vitolo MI, Argani P, DeMarzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C,

Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH. Tamoxifen-stimulated growth

of breast cancer due to p21 loss. Proceedings of the National Academy of Sciences, USA. 2008 Jan 8;105(1):288-93. PMCID: PMC2224203; PMID: 18162533

109. Reed CE, Graham A, Hoda RS, Khoor A, Garrett-Mayer E, Wallace MB, Mitas M. A simple two-gene prognostic model

for adenocarcinoma of the lung. Journal of Thoracic and Cardiovascular Surgery. March 2008; 135(3): 627-634. PMID:

18329483

110. Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo

AM, Herman JG. Impact of DNA Methylation on the identification of aggressive prostate cancer. Urology, 2008 Apr 1.

PMID: 18387661

111. Diaz-Montero CM, Salem M, Garrett-Mayer E, Cole DJ, Montero AJ. Increased Levels of Circulating Myeloid-Derived

Suppressor Cells in Solid Tumor Patients Correlate With Advanced Clinical Cancer Stage, Increased Tumor Burden, and

Cyclophosphamide Containing Chemotherapy. Cancer Immunology, Immunotherapy, 30 April 2008. PMID: 18446337

112. McRackan TR, Watkins JM, Herrin AE, Garrett-Mayer E, Sharma AK, Day TA, Gillespie MB. Effect of Body Mass

Index on Chemoradiation Outcomes in Head and Neck Cancer. Laryngoscope, 2008 Jul;118(7):1180-5. PMID: 18475213

113. Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E.

Phase II trial of the oral farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) as maintenance therapy in first

complete remission in adults with acute myelogenous leukemia and poor risk features. Clinical Cancer Research, 2008

May 15;14(10):3077-82. PMID: 18483374

114. Snyder CF, Garrett-Mayer E, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. Symptoms,

Supportive Care Needs, and Function in Cancer Patients: How Are They Related? Quality of Life Research, May 21,

2008. PMID: 18493865

115. Shrout J, Yousefzadeh M, Dodd A, Kirven K, Blum C, Graham A, Benjamin K, Hoda R, Krishna M, Romano M, Wallace

M, Garrett-Mayer E, Mitas M. beta(2)microglobulin mRNA expression ratios are prognostic for lymph node metastasis

in colorectal cancer patients. British Journal of Cancer, 2008 Jun 17;98(12):1999-2005. PMID: 18506145

116. Moussa O, Ashton AW, Fraig M, Garrett-Mayer E, Ghoneim MA, Halushka PV, Watson DK. Novel Role of

Thromboxane Receptors {beta} Isoform in Bladder Cancer Pathogenesis. Cancer Res. 2008 Jun 1;68(11):4097-4104.

PMID: 18519668

117. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA,

Laheru D, Donnehower RC, Garrett-Mayer E, Baker SD, Hidalgo M. Pharmacodynamic-guided modified continuous

reassessment method (mCRM) –based, dose finding study of rapamycin (sirolimus) in adult patients with solid tumors.

Journal of Clinical Oncology 2008 Sep 1;26(25):4172-9. PMID: 18757332

118. Su S-C, Caffo B, Garrett-Mayer E, Bassett SS. Modified test statistics by inter-voxel variance shrinkage with an

application to fMRI. Biostatistics 2009 Apr;10(2):219-27. PMID: 18723853

119. Blum C, Graham A, Yousefzadeh M, Shrout J, Krishna M, Hoda R, Hoda R, Cole DJ, Garrett-Mayer E, Reed C, Wallace

M, Mitas M. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer.

International Journal of Oncology 2008 Sep;33(3):579-84. PMID: 18695889

120. Hall PD, Beagle KL, Garrett-Mayer E, Frankel AE. Reducing Anti-DT IgG Concentrations to Improve the efficacy of a

Diphtheria Fusion Protein. Anti-Cancer Drugs. 2008 Nov;19(10):1007-1011. PMID: 18827566

121. Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith DB, Ironside V,

Talbot T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore S, Levis MK, Wright JJ, Garrett-Mayer

ELIZABETH GARRETT-MAYER PAGE 23 OF 31 MAY 16

E*, Kaufmann SH*. Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia: A

Preclinical and Phase I Trial of the Farnesyltransferase Inhibitor Tipifarnib (R115777, Zarnestra) Combined with

Etoposide. Blood, 2009 May 14;113(20):4841-52. (* denotes equal contribution of last two senior authors). PMID:

19109557

122. Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, Sherman CA, Sharma AK. Factors

associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-

stage small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2009;74:1108-1113. PMID: 19084345

123. Watkins JM, Marshall DT, Patel S, Giglio P, Herrin AE, Garrett-Mayer E, Jenrette JM. High-Dose Radiotherapy to 78

Gy With or Without Temozolomide for High Grade Gliomas. Journal of Neuro-Oncology. 2009 Jul;93(3):343-8. PMID:

19142584

124. Watkins JM, Shirai KS, Wahlquist AE, Stuart RK, Chaudhary UB, Garrett-Mayer E, Day TA, Gillespie MB, Sharma

AK. Toxicity and survival outcomes of hyperfractionated re-irradiation split-course radiotherapy and concurrent

chemotherapy in loco-regionally recurrent, previously irradiated head and neck cancers. Head & Neck, 2009;31:493-502.

PMID: 19156831

125. Nietert PJ, Ravenel JG, Leue WM, Miller JV, Taylor KK, Garrett-Mayer E, Silvestri GA. Imprecision in automated

volume measurements of pulmonary nodules and its effect on the level of uncertainty in volume doubling time estimation.

Chest. 2009 June; 135(6): 1580-7. PMID: 19141526

126. Nonemaker JM, Garrett-Mayer E, Carpenter MJ, Ford MW, Silvestri G, Lackland DT, Alberg AJ. The Risk of Dying

from Lung Cancer by Race: A Prospective Cohort Study in a Biracial Cohort in Charleston, South Carolina. Annals of

Epidemiology. 2009 May;19(5):304-10. PMID: 19269855

127. Zellars RC, Stearns V, Frassica D, Asrari F, Tsangaris T, Myers L, DiPasquale S, Lange J, Jacobs L, Emens L, Armstrong

D, Fetting J, Garrett-Mayer E, Davidson NE, Wolff AC. Partial Breast Irradiation and Concurrent dose-dense

Doxorubicin and Cyclophosphamide. Journal of Clinical Oncology. 2009 Jun 10; 27(1):2816-22. PMID: 19332718

128. Loeb DM, Garrett-Mayer E, Hobbs R, Prideaux AR, Sgouros G, Shokek O, Wharam MD, Scott T, Schwartz CL. Dose-

Finding Study of 153Sm-EDTMP in Patients with Poor Prognosis Osteosarcoma. Cancer. 2009 Jun 1;115(11):2514-22]

PMID: 19338063

129. Carpenter MJ, Garrett-Mayer E, Vitoc C, Cartmell K, Biggers S, Alberg A. Adolescent Light and Intermittent Smokers:

Favorable Views of Tobacco Yet Receptive to Cessation. Nicotine and Tobacco Research. 2009 Apr;11(4):348-55.

PMID: 19366985

130. Yang C, Garrett-Mayer E, Schneider JS,Gollomp SM,Tilley BC. Repeatable Battery for Assessment of

Neuropsychological Status in Early Parkinson’s Disease. Movement Disorders, 2009 Jul 30; 24(10): 1453-60. PMID:

19452561.

131. Snyder CF, Garrett-Mayer E, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW.

Concordance of cancer patients' function, symptoms, and supportive care needs. Quality of Life Research. 2009 Oct;

18(8):991-8. PMID: 19657724.

132. Berenholtz SM, Pham JC, Garrett-Mayer E, Atchison CW, Kostuik JP, Cohen DB, Nundy S, Dorman T, Ness PM, Klag

MJ, Pronovost PJ, Kebaish KM. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal

surgery. Spine (Phila Pa 1976). 2009 Sep 1;34(19):2096-103. PMID: 19730217.

133. Harper JL, Watkins JM, Zauls AJ, Wahlquist AE, M.S, Garrett-Mayer E, Baker MK, Cole DJ, Dragun AE, Jenrette JM.

Six-year experience: long term disease control outcomes for partial breast irradiation using MammoSite balloon

brachytherapy. Am J Surg. 2010 Feb; 199(2): 204-9 PMID: 19837390.

134. Cunningham JC, Montero AJ, Garrett-Mayer E, Berkel HJ, Ely B. Racial differences in the incidence of breast cancer

subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes and Control 2010 Mar; 21(3):

399-409. PMID: 20024610

135. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of Survival following First-Line

ELIZABETH GARRETT-MAYER PAGE 24 OF 31 MAY 16

Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. Clinical Cancer Research, 2010 Jan 1; 16(1):

203-211.

136. Watkins JM, Zauls AJ, Wahlquist AH, Shirai K, Garrett-Mayer E, Gillespie MB, Day TA, Sharma AK. Low-dose

weekly platinum-based chemoradiation for advanced head/neck cancer. Laryngoscope Feb 2010 120(2):236-42.

137. Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C,

Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI. K562/GM-CSF immunotherapy reduces tumor burden

in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010 Jan 1;16(1):338-

47. PMID: 20048335.

138. Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk

febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010 Feb;19(2):231-7 PubMed PMID: 20069435.

139. Nalugoda F, Wagman J, Kiddugavu M, Kiwanuka N, Garrett E, Gray RH, Serwadda D, Wawer MJ, Emanuel EJ. Is there

coercion or undue inducement to participate in health research in developing countries? An example from Rakai, Uganda. J

Clin Ethics. 2009 Summer;20(2):141-9. PubMed PMID: 19554819.

140. Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, Sherman CA, Sharma AK. Factors

associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-

stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;74:1108-1113. PMID: 19084345

141. Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to Phase 1 Clinical Trial Design Focused on Safety,

Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer

Institute Investigational Drug Steering Committee. Clin Cancer Res. 2010 Mar 15; 16(6):1726-36. PMID: 20215542

142. El-Zawahry AM, Clarke HS, Eskridge MR, Rieter W, Onicescu G, Garrett-Mayer E, Gordon LL, Keane TE. Capromab

Pendetide Scanning Has a Potential Role in Optimizing Patient Selection for Salvage Cryosurgical Ablation of the Prostate.

Urology, 2010 Nov; 76(5): 1162-7.

143. Watkins JM, Fortney JA, Wahlquist AH, Shirai K, Garrett-Mayer E, Aguero EG, Sherman CA, Turrisi AT, Sharma AK.

Once-daily radiotherapy to >59.4 Gy versus twice-daily radiotherapy to >45 Gy with concurrent chemotherapy for limited-

stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. 2010 Jun;28(5):340-8.

PMID: 20585921

144. Ford ME, Wahlquist AE, Ridgeway C, Streets J, Mitchum KA, Harper RR Jr, Hamilton I, Etheredge JJ, Jefferson MS,

Varner H, Campbell K, Garrett-Mayer E. Evaluating an Intervention to Increase Cancer Knowledge in Racially Diverse

Communities in South Carolina. Patient Educ Couns. 2011 May; 83(2)” 256-60. PMID: 20674239

145. Ruppert BN, Watkins, JM, Shirai K, Wahlquist AE, Garrett-Mayer E, Aguero EG, Sherman CA, Reed CE, Sharma AK.

Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal

cancer. Am J Clin Oncol 2010;33:346-352.

146. Watkins JM, Wahlquist AE, Zauls AJ, Shirai K, Garrett-Mayer E, Aguero EG, Silvestri GA, Sherman CA, Sharma AK.

Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer (SCLC): disease

control, patterns of failure, and survival. J Med Imaging Radiat Oncol 2010;54:483-489.

147. Zauls AJ, Watkins JM, Wahlquist AE, Brackett NC, Aguero EG, Baker MK, Jenrette JM, Garrett-Mayer E, Harper JL.

Outcomes in Women Treated with MammoSite Brachytherapy or Whole Breast Irradiation Stratified by ASTRO

Accelerated Partial Breast Irradiation Consensus Statement Groups. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1): 21-9.

PMID: 20951508.

148. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin

HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 2011 Jan 1; 300(1): 66-78. PMID: 20980099.

149. Watkins JM, Wahlquist AE, Zauls AJ, Fields EC, Garrett-Mayer E, Aguero EG, Silvestri GA, Sharma AK. High-dose

fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small cell lung cancer. J Med Imaging Radiat

Oncol. 2010 Dec; 54(6): 554-61 PMID: 21199434.

ELIZABETH GARRETT-MAYER PAGE 25 OF 31 MAY 16

150. Fisher CS, Cole DJ, Mitas M, Garrett-Meyer E (sic), Metcalf JS, Gillanders WE, Mikhitarian K, Urist MM, Mann GB,

Doherty G, Herrmann VM, Hill AD, Eremin O, El-Sheemy M, Orr RK, Valle AA, Henderson MA, Dewitty RL, Sugg SL,

Frykberg E, Yeh K, Bell RM, Baker MK. Molecular detection of micrometastatic breast cancer in histopathology-negative

axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of a prospective multi-institutional cohort

study. Ann Surg Oncol. 2010 Oct;17 Suppl 3:312-20. PubMed PMID:20853052.

151. Scharpf R, Iacobuzio-Donahue CA, Cope L, Ruczinski I, Lakkar S, Garrett-Mayer E, Parmigiani G. Cross-platform

comparison of two pancreatic cancer phenotypes. Cancer Informatics. 2010 Nov 1; 9:257-264.

152. Leoutsakos JM, Bandeen-Roche K, Garrett-Mayer E, Zandi P. Incorporating Scientific Knowledge into Phenotype

Development: Penalized Latent Class Regression. Statistics in Medicine. 2011 Mar 30; 30(7): 784-98 PMID: 21394753.

153. Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Feting JH, Emens LA,

Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel Metabolism is Not Altered by Imatinib: Findings from an Early

Phase Study in Metastatic Breast Cancer. Breast Cancer Research and Treatment 2011 May; 127(1): 153-62. PMID:

213508820.

154. Van Meter E, Garrett-Mayer E, Bandyopadhay D. Proportional odds model for dose finding clinical trial designs with

ordinal toxicity grading. Statistics in Medicine. 2011Jun 30; 30(17): 2070-80. PMID: 21344472; PMCID: PMC3117067.

155. Kearney PL, Watkins JL, Shirai K, Wahlquist AE, Fortney JA, Garrett-Mayer E, Gillespie MB, Sharma AK. Salvage

Resection for Isolated Local and/or Regional Failure of Head/Neck Cancer Following Definitive Concurrent

Chemoradiotherapy Case Series and Review of the Literature. McGill Journal of Medicine 2011 Jun; 13(2): 29.

156. Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS. A Novel Extracellular Hsp90

Meditated Function for LRP1 Regulates EphA2 Dependent Gioblastoma Invasion. PLoS One. 2011 Mar 8; 6(3): e17649.

PMID: 21408136.

157. Ryan, K.K., Garrett-Mayer, E., Alberg, A.J., Cartmell, K.B., & Carpenter, M.J. Predictors of cessation pharmacotherapy

use among African American and non-Hispanic white smokers. Nicotine & Tobacco Research. 2011 Aug;13(8):646-52.

PMID: 21464200.

158. Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Combination Therapy

of recurrent prostate cancer with proteasome inhibitor Bortezomib plus hormone blockade. Cancer Biol Ther, 2011 July

15; 12(2): 119-24. PMID: 21532336.

159. Tanner NT, Watson P, Boylan A, Memoli JS, Pastis N, Taylor K, Garrett-Mayer E, Silvestri GA. Utilizing endobronchial

ultrasound with fine-needle aspiration to obtain tissue for molecular analysis: a single-center experience. J Bronchology

Interv Pulmonol 2011 Oct; 18(4):317-21. PMIS 23208625

160. Wang Memoli, J, El-Bayoumi E, Pastis N, Tanner N, Gomez M, Huggins J, Onicescu G, Garrett-Mayer E, Armeson K,

Taylor K, Silvestri G. Using EBUS Features to Predict Lymph Node Metastasis in Patients with Lung Cancer. Chest, 2011

Dec; 140(6): 1550-6. PMID: 21636663; PMCID: PMC3231960.

161. Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G,

Garrett-Mayer E, Montero AJ, Bronte V, Mandruzzato S. A human promyelocytic-like population is responsible for the

immune suppression mediated by myeloid-derived suppressor cells. Blood, 2011 Aug 25; 118(8): 2254-65. PMID:

21734236.

162. Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS,

Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon G, Shirai K, Ogretmen B. Results of a Phase II Trial of

Gemcitabine plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-ceramide as a Novel

Biomarker for Monitoring Response. Clin Cancer Res. 2011 Sep 15; 17(18): 6097-105. PMID 21791630. PMCID:

PMC3176980.

163. Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers P, Wright LA,

Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson

NE, Stearns V. Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant

Anastrozole. Cancer Prevention Research. 2011 Dec; 4(12): 1993-2001. PMID: 21885816.

ELIZABETH GARRETT-MAYER PAGE 26 OF 31 MAY 16

164. Karp JE, Vener TI, Raponi M, Greer J, Ritchie EK, Morris LE, Smith BD, Feldman EJ, Gore SD, Levis MJ, Galkin S,

Malek S, Gocke CD, Roboz GR, Carraway HE, McDevitt MA, Derecho C, Palma J, Wang Y, Kaufmann SH, Wright JJ,

Garrett-Mayer E. Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly

adults with newly diagnosed acute myelogenous leukemia. Blood. 2012 Jan 5;119(1):55-63.

165. Curran JN, Garrett-Mayer E, Carpenter MJ, Ford ME, Silvestri GA, Lackland DT, Alberg AJ. Cigarette Smoking and the

Risk of Dying from Tobacco-related Malignancies by Race. Anticancer Research . 2011 Nov; 31(11):3891-5.

166. Logan S, Nicholas J, Carpenter L, King L, Garrett-Mayer E, Charles J. High Prescription Drug Utilization and

Associated Costs among Medicaid-eligible Children with Autism Spectrum Disorders Identified by a Population-based

Surveillance Network. Annals of Epidemiology.2012 Jan; 22(1): 1-8.

167. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL,

Abbruzzese JL, Thomas MB. Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and

Predictors of Outcome: Final Results of a Phase II Trial. Oncology. 2012 Feb 7;82(2):67-74.

168. Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E

(sic), Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, Glück S. Phase 2 study of neoadjuvant

treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with

HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat. 2012 Feb;132(1):215-23. PMCID:

PMC3697917.

169. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, Ambrose LH, Kindy MS, Gattoni-Celli S.

Vitamin D3 supplementation at 4,000 IU per day for one year results in a decrease of positive cores at repeat biopsy in

subjects with low-risk prostate cancer under active surveillance. The Journal of Clinical Endocrinology & Metabolism,

2012 Apr 16 [Epub ahead of print].

170. Burton JH, Garrett-Mayer E, Thamm DH. Evaluation of a 15 week CHOP Protocol for the Treatment of Canine

Multicentric Lymphoma. Veterinary and Comparative Oncology, 2012 May 2 [Epub ahead of print].

171. Van Meter E, Garrett-Mayer E, Bandyopadhyay D. Dose-finding clinical trial design for ordinal toxicity grades using the

continual ratio model: an extension of the continual reassessment method. Clinical Trials. 2012 Apr 30 [Epub ahead of

print].

172. Hudspeth MP, Heath TS, Chiuzan C, Garrett-Mayer E, Nista E, Burton L, Ragucci D. Folinic acid administration after

methotrexate graft-versus-host disease prophylaxis in pediatric allogeneic stem cell transplantation. Bone Marrow

Transplantation. 21 May 2012 [Epub ahead of print].

173. Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Gore SD, Greer JM, Drye DM, Mackey K, Dorcy KS,

Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM.

A randomized Phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside

and mitoxantrone (FLAM) for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 2012

June 24 [Epub ahead of print].

174. Taylor R, Opfermann K, Jones BD, Terwilliger LE, McDonald DG, Ashenafi MS, Garrett-Meyer E [sic], Marshall DT.

Comparison of radiation treatment delivery for pancreatic cancer: Linac intensity-modulated radiotherapy versus helical

tomotherapy. J Med Imaging Radiat Oncol. 2012 Jun;56(3):332-7. Epub 2012 Apr 11. PubMed PMID: 22697333.

175. Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, Murali AK, Lyons GE, Li M, Spivey ND, Norell

H, Martins da Palma T, Onicescu G, Diaz-Montero CM, Garrett-Mayer E, Cole DJ, Le Poole IC, Nishimura MI. A

Coreceptor-Independent Transgenic Human TCR Mediates Anti-Tumor and Anti-Self Immunity in Mice. Journal of

Immunology. 2012 Jul 13 [Epub ahead of print].

176. Garrett-Mayer E, Wagner CL, Hollis BW, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation (4000 IU per day for

one year) eliminates differences in circulating 25(OH)D between African-American and Caucasian men. The American

Journal of Clinical Nutrition. 2012 Aug; 96(2): 332-6.

ELIZABETH GARRETT-MAYER PAGE 27 OF 31 MAY 16

177. Ford ME, Wahquist AH, Blake R, Green C, Streets J, Fuller E, Johnson E, Jefferson MS, Etheredge JW, Varner H,

Johnson S, Glover SH, Turner DP, Garrett-Mayer E. Assessing an intervention to improve clinical trial perceptions

among predominantly African American communities in South Carolina. Progress in Community Health Partnerships:

Research Education and Action, 2012 Fall; 6(3): 249-63.

178. Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn

RA, Hidalgo M. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

Neoplasia. 2012 Aug 14; 14(8):690—701.

179. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam

SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, Stahelin RV, Perrotti D, Ogretmen B.

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-

RIPK1-dependent necroptosis. EMBO Mol Med. 2012 Nov 25 [Epub ahead of print].

180. Opferman K., Wahlquist AE, Garrett-Mayer E, Shridhar R, Cannick L, Marshall DT. Adjuvant Radiotherapy and Lymph

Node Status for Pancreatic Cancer: Results of a Study from the Surveillance, Epidemiology, and End Results (SEER)

Registry Data. American Journal of Clinical Oncology. 2012 Dec 1 [Epub ahead of print].

181. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-

risk prostate cancer, and health disparities. The Journal of Steroid Biochemistry and Molecular Biology. 2012 Dec 7.

[Epub ahead of print].

182. Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman C, Lacek AT,

Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, Mehrotra S, Hernandez C, Nishimura MI,

Guevara-Patino JA, Le Poole IC. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Science Translational

Medicine 2013 Feb 27; 5(174).

183. Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA,

Zhao M, Watkins SP Jr, McLeod HL, Davidson NE, Wolff AC. Fixed-dose capecitabine is feasible: results from a

pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat. 2013 May;139(1):135-

43. doi: 10.1007/s10549-013-2516-z. PMID: 23588952 NIHMS: 468395.

184. Nassarre P, Roche J, Potiron VN, Howe P, Orch C, Baron A, Garrett-Mayer E, Drabkin H. Neuropilin-2 is upregulated

in lung cancer cells during TGFβ1-induced epithelialmesenchymal transition. Cancer Res. 2013 Dec 1;73(23):7111-21.

185. Rossmann C, Garrett-Mayer E, Haemmerich D. Dynamics of tissue shrinkage during ablative temperature exposures.

Physiol. Meas. 35 (2014) 55-67.

186. Morales C, Rachidi S, Hong F, Sun S, Ouyang X, Wallace C, Zhang Y, Garret-Mayer E (sic), Wu J, Liu B, Li Z. Immune

chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis. Cancer Research, 2014 Jan

15; 74(2):446-59.

187. Gosnell H, Kasman LM, Potta T, Vu L, Garrett-Mayer E, Rege K, Voelkel-Johnson C. Polymer-Enhanced Adenoviral

Delivery Increases Gene Expression in an Orthotopic Model of Bladder Cancer. Journal of Controlled Release, 2013 Dec

24: 176C:35-43.

188. Zellars R, Bravo PE, Tryggestad E, Hopfer K, Myers L, Tahari A, Asrari F, Ziessman H, Garrett-Mayer E. SPECT analysis

of Cardiac Perfusion Changes After Whole Breast/Chest Wall (BCW) Radiation Therapy with or without Active Breathing

Coordinator (ABC): Results of a Randomized Phase III Trial. International Journal of Radiation Oncology Biology and

Physics, 2014 Mar 15;88(4):778-85.

189. Esnaola N, Chaudhary U, O’Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ,

Romagnuolo J, Orwat K, Marshall D. Phase II Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by

Selective Capecitabine-Based Chemoradiation in Patients with Nonmetastatic, Locally Advanced Pancreatic

Cancer. International Journal of Radiation Oncology, Biology and Physics. Int J Radiat Oncol Biol Phys. 2014

Mar 15;88(4):837-44.

ELIZABETH GARRETT-MAYER PAGE 28 OF 31 MAY 16

190. Lee M Ellis, David S Bernstein, Emile E Voest, Jordan D Berlin, Daniel J Sargent, Patricia Cortazar, Elizabeth Garrett-

Mayer, Roy S Herbst, Rogerio C Lilenbaum, Camelia Sima, Alan P Venook, Mithat Gönen, Richard L Schilsky, Neal J

Meropol, and Lowell E Schnipper. ASCO Perspective: Raising the Bar for Clinical Trials by Defining Clinically

Meaningful Outcomes. Journal of Clinical Oncology, 2014 Apr 20; 32(12): 1277-80.

191. Grass GD, Cooper SL, Armeson K, Garrett-Mayer E, Sharma A. Cervical Esophageal Cancer: A Population Based

Study. Head and Neck, 2014 Mar 11. [Epub ahead of print].

192. Mathew AR, Wahlquist AE, Garrett-Mayer E, Gray KM, Saladin ME, Carpenter MJ. Affective Motives for Smoking

Among Early Stage Smokers. Nicotine Tob Res. 2014 Jun 12. pii: ntu093. [Epub ahead of print] PubMed PMID:

24924155.

193. Logan SL, Carpenter L, Leslie RS, Hunt KS, Garrett-Mayer E, Charles J, Nicholas JS. Rates and Predictors of Adherence

to Psychotropic Medications in Children with Autism Spectrum Disorders. J Autism Dev Disord. 2014 Jun 15. [Epub

ahead of print] PubMed PMID: 24929833.

194. Eby JM, Kang HK, Klarquist J, Chatterjee S, Mosenson JA, Nishimura MI, Garrett-Mayer E, Jack Longley B, Engelhard

VH, Mehrotra S, Le Poole IC. Immune Responses In A Mouse Model Of Vitiligo With Spontaneous Epidermal De- And

Repigmentation. Pigment Cell Melanoma Res. 2014 Jun 17. doi: 10.1111/pcmr.12284. [Epub ahead of print] PubMed PMID:

24935676.

195. Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt

K, Berg M, Uram J, Dauses T, Fetting JH, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA.

A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for

HER-2+ Metastatic Breast Cancer. Cancer Immunology Research. 2014 Aug 12. Epub ahead of print.

196. Kummetha Venketa JK, An N, Stuart R, Costa L, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E, Wan

Z, Ogretmen B, Smith C, Kang Y. 1Inhibition of Sphingosine Kinase 2 Down-regulates the Expression of c-Myc and Mcl-1

and Induces Apoptosis in Multiple Myeloma. Blood. 2914 Aug 13. Epub ahead of print.

197. Sobelesky PM, Halushka P, Garrett-Mayer E, Smith MT, Moussa O. Regulation of the Tumor Suppressor FOXO3 by the

Thromboxane-A2 Receptors in Urothelial Cancer. 2014 Sep 9;9(9):e107530 PMCID: PMC4159332.

198. Kesarwani P, Al-Khami AA, Scurti G, Thyagarajan K, Kaur N, Husain S, Fang Q, Naga O, Simms P, Beeson G, Voelkel-

Johnson C, Garrett-Mayer E, Beeson CC, Nishimura MI, Mehrotra S. Promoting Thiol Expression Increases The Durability

of Antitumor T cell Functions. Cancer Research, 2014 Aug 2 [Epub ahead of print].

199. Turner-Ivey B, Guest ST, Irish JC, Kappler CS, Garrett-Mayer E, Wilson RC, Ethier SP. KAT6A, a Chromatin Modifier

from the 8p11-p12 Amplicon is a Candidate Oncogene in Luminal Breast Cancer. Neoplasia. 2014 Aug; 16(8): 644-655.

PMCID in progress.

200. Chiuzan C, Garrett-Mayer E, Yeatts S. A likelihood-based approach for computing the operating characteristics of the 3+3

phase I clinical trial design with extensions to other A+B designs. Clinical Trials. 2014 Oct 27 [Epub ahead of print]. PMCID

in progress.

201. Somaiah N, Fidler M, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon G. Epidermal

growth factor receptor (EGFR) mutations are exceptionally rare in Thyroid transcription factor (TTF-1) negative

adenocarcinomas of the lung. Oncoscience. 2014 Aug 7;1(8):522-8. eCollection 2014. PMCID: PMC4278331

202. Kappler CS, Guest ST, Irish JC, Garrett-Mayer E, Kratche Z, Wilson RC, Ethier SP. Oncogenic signaling in amphiregulin

and RGFR-expression PTEN-null human breast cancer. Mol Onc 2014 Oct 23. [Epub ahead of print].

203. Smolka A, Halushka P, Garrett-Mayer E. The Faculty Costs to Educate a Biomedical Sciences Graduate Student. Life

Sciences Education. 2015 Mar 2.

204. Rubinstein MP, Su EW, Suriano S, Cloud CA, Andrijauskaite K, Kesarwani P, Schwartz KM, Williams K, Johnson CB, Li

M, Scurti GM, Salem ML, Paulos CM, Garrett-Mayer E, Mehrotra S, Cole DJ. IL-12 enhances the function and anti-

tumor activity in murine and human CD8+ T cells. Cancer Immunology & Immunotherapy. 2015 Feb 13.

ELIZABETH GARRETT-MAYER PAGE 29 OF 31 MAY 16

205. Harper JL, DeCosta AM, Garrett-Mayer E, Sterba KR. Incorporating Patient Satisfaction Metrics In Assessing

Multidisciplinary Breast Cancer Care Quality. Southern Medical Journal 2015 Jun; 108(6):372-6 PMCID: PMC4470304

(available 2016-06-01.

206. Tirodkar TS, Lu P, Bai A, Scheffel MA, Gencer S, Garrett-Mayer E, Bielawska A, Ogretmen B, Voelkel-Johnson C.

Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-Terminal Kinase (JNK)-

Dependent Manner. The Journal of Biological Chemistry, Apr 3, 2015 (Epub).

207. Logan SL, Carpenter L, Leslie RS, Garrett-Mayer E, Hunt KJ, Charles J, Nicholas JS. Aberrant behaviors and co-occurring

conditions as predictors of psychotropic polypharmacy among children with autism spectrum disorders. J Child Adolesc

Psychopharmacol 2015 Apr 28 [Epub ahead of print].

208. Rhome RM, Wahlquist AE, Cooper, SL, Hill E, Garrett-Mayer E, Harper JL. Investigation of Epidemiological Factors as

Barriers to Indicated Radiation Therapy in Post−mastectomy Breast Cancer Patients in South Carolina. Journal of the South

Carolina Medical Association. 2015 March/April; 111(1):14-18.

209. Panneer Selvam S, De Palma RM, Oaks JJ, Oleinik N, Peterson YK, Stahelin RV, Skordalakes E, Ponnusamy S, Garrett-

Mayer E, Smith CD, Ogretmen B. Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery

by allosterically mimicking protein phosphorylation. Sci Signal. 2015 Jun 16;8(381).

210. Grass GD, Cooper SL, Armeson K, Garrett-Mayer E, Sharma A. Cervical esophageal cancer: A population-based

study. Head Neck. 2015 Jun;37(6):808-14. doi: 10.1002/hed.23678. Epub 2014 Jun 19. PubMed PMID: 24616217.

211. Marvella E Ford, Ph.D.; Wei Wei; Leslie A Moore; Dana R Burshell; Kimberly Cannady, Ph.D.; Franshawn Mack; Nnadozie

Ezerioha; Kelley Ercole; Elizabeth Garrett-Mayer, Ph.D. Evaluating the Reliability of the Attitudes To Randomized Trial

Questionnaire (ARTQ) in a Predominantly African American Sample. SpringerPlus, 2015 Aug 12; 4:411.

212. Andrijauskaite K, Suriano S, Cloud CA, Li M, Kesarwani P, Stefanik LS, Moxley KM, Salem ML, Garrett-Mayer E, Paulos

CM, Mehrotra S, Kochenderfer JN, Cole DJ, Rubinstein MP. IL-12 conditioning improves retrovirally mediated transduction

efficiency of CD8(+) T cells. Cancer Gene Ther. 2015 Jul;22(7):360-7. doi: 10.1038/cgt.2015.28. Epub 2015 Jul 17. PubMed

PMID: 26182912.

213. Johnson CB, Riesenberg BP, May BR, Gilreath SC, Li G, Staveley-O'Carroll KF, Garrett-Mayer E, Mehrotra S, Cole DJ,

Rubinstein MP. Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα

Dependent.Cancer Immunol Res. 2015 Aug 21. [Epub ahead of print] PubMed PMID: 26297711.

214. Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR,Kraveka JM, Smith CD, Voelkel-

Johnson C. The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in

accumulation of dihydroceramides in vitro and in vivo. Mol Cancer Ther. 2015 Oct 22. pii: molcanther.0279.2015. [Epub

ahead of print] PubMed PMID: 26494858.

215. Su EW, Moore CJ, Suriano S, Johnson CB, Songalia N, Patterson A, Neitzke DJ, Andrijauskaite K, Garrett-Mayer E,

Mehrotra S, Paulos CM, Doedens AL, Goldrath AW, Li Z, Cole DJ, Rubinstein MP. IL-2Rα mediates temporal regulation

of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28;7(311):311ra170. doi:

10.1126/scitranslmed.aac8155. PubMed PMID: 26511507.

216. Timothy T. Spear, Glenda G. Callender, Jeffrey J. Roszkowski, Kelly M. Moxley, Kendra C. Foley, David C. Murray,

Gina M. Scurti, Patricia Simms, Mingli Li, Justin Thomas, Alexander Langerman, Elizabeth Garrett-Mayer, Yi. Zhang,

and Michael I. Nishimura, TCR gene-modified T cells can efficiently treat established hepatitis C associated hepatocellular

carcinoma tumors. Cancer Immunology, Immunotherapy. 2016 March; 65(3): 293-304.

217. Spear TT, Riley TP, Lyons GE, Callender GG, Roszkowski JJ, Wang Y, Simms PE, Scurti GM, Foley KC, Murray DC,

Hellman LM, McMahan RH, Iwashima M, Garrett-Mayer E, Rosen HR, Baker BM, Nishimura MI. Hepatitis C virus-

cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc

Biol. 2016 Feb 26.

218. Guest S, Krachte Z, Irish, J, Wilson R, Haddad R, Gray J, Garrett-Mayer E, Ethier S. Functional Oncogene Signatures

Guide Rationally Designed Combination Therapies to Synergistically Induce Breast Cancer Cell Death. Accepted,

ELIZABETH GARRETT-MAYER PAGE 30 OF 31 MAY 16

Oncotarget.

219. Carpenter MJ, Wahlquist AE, Burris JL, Gray KM, Garrett-Mayer E, Cumming KM, Alberg AJ. Snus undermines quit

attempts but not abstinence: a randomized clinical trial among US smokers. Tobacco Control. 2016 Apr 12.

UNON- PEER REVIEWED:U

1. HUZeger SL, Garrett ES. Rejoinder to latent class model diagnosis from a frequentist point of view. Biometrics. 2003; 59(1):

197-198UH.

2. HUBaker S, Garrett E, Giles F. Troxcitabine in patients with refractory leukemia -in reply. Journal of Clinical Oncology.

2002; 20(15): 3356-3361.U

3. HUGitlin JN, Cook LL, Linton OW, Garrett-Mayer E. Response to letters on B-readers study. Academic Radiology. 2004;

11(12):1402-1404.U

USCHOLARLY BOOKS AND MONOGRAPHS:

1. Parmigiani G, Garrett ES, Irizarry RA, Zeger SL. The Analysis of Gene Expression Data: Methods and Software. Springer:

New York, 2003.

2. Hidalgo M, Eckhardt SG, Garrett-Mayer E, Clendenin N. Principles of Anticancer Drug Development. Springer: New

York, 2011.

UCHAPTERS IN SCHOLARLY BOOKS AND MONOGRAPHS

1. Garrett ES, Parmigiani G. POE: Statistical Methods for Qualitative Analysis of Gene Expression. In The Analysis of Gene

Expression Data: Methods and Software (eds. G Parmigiani, ES Garrett, RA Irizarry, SL Zeger) Chapter 16, Springer: New

York, 2003.

2. Parmigiani G, Garrett ES, Irizarry RA, Zeger SL. The Analysis of Gene Expression Data: An Overview of Methods and

Software. In The Analysis of Gene Expression Data: Methods and Software (eds. G. Parmigiani, E.S. Garrett, R.A. Irizarry,

S.L. Zeger) Chapter 1, Springer: New York, 2003.

3. Garrett ES. Overview of Standard Clustering Approaches for Gene Microarray Data Analysis. In DNA Microarrays and

Statistical Genomic Techniques: Design, Analyis, and Interpretation of Experiments (eds. D. Allison, M. Beasley, J.

Edwards, G. Page). Chapter 3, Marcel-Dekker: New York, 2006.

4. Garrett ES. Latent Class Analysis. In Encyclopedia of Biopharmaceutical Statistics, ed. Shein-Chung Chow. Marcel

Dekker: New York, 2003.

5. Garrett-Mayer E, Scharpf R. Models for probability of under- and over-expression: The POE scale. In Bayesian Inference

for Gene Expression and Proteomics, ed. K.-A. Do, P. Mueller, M. Vannucci. Chapter 13, Cambridge University Press:

Cambridge, 2006.

6. Garrett-Mayer E, Parmigiani G. Clustering and classification methods for gene expression data analysis. In DNA

Microarrays (Advanced Methods), ed. U. Nuber. Taylor and Francis Group: New York, 2005.

7. Garrett-Mayer, E. Application of Novel Designs in Phase I Trials. In Wiley Encyclopedia of Clinical Trials, ed. L.Sullivan.

8. Garrett-Mayer, E. Adaptive Clinical Trial Design in Oncology. In Oncology Clinical Trials, ed. Kelly & Halabi. New

York: Demos Medical, 2010.

9. Hill EG, Garrett-Mayer E. Basic Biostatistics for the Clinical Trialist. In Principles of Anticancer Drug Development. Ed.

Hidalgo, Eckhardt, Garrett-Mayer, Clendeninn. Springer: New York, 2011.

UNON-PEER REVIEWED ELECTRONIC PUBLICATIONS:

1. HUGarrett ES, Parmigiani GP. A Nested Unsupervised Approach to Identifying Novel Molecular Subtypes. Johns Hopkins

ELIZABETH GARRETT-MAYER PAGE 31 OF 31 MAY 16

University, Dept. of Biostatistics Working Paper 5, October 6, 2003. U

2. HUGarrett ES, Miech R, Owens P, Eaton W, Zeger S. Checking assumptions in latent class regression models via a markov

chain monte carlo estimation approach: an application to depression and socio-economic status. Johns Hopkins University,

Dept. of Biostatistics Working Paper 17, January 15, 2003. U

3. HUCope L, Zhong X, Garrett-Mayer E, Parmigiani G. MergeMaid: R Tools for Merging and Cross-Study Validation of Gene

Expression Data. Johns Hopkins University, Dept. of Biostatistics Working Paper 53, 2004. U

4. HUGarrett-Mayer E, Goodman SN, Hruban RH. The Proportional Odds Model for Assessing Rater Agreement with Multiple

Modalities. Johns Hopkins University, Dept. of Biostatistics Working Paper 64, 2004. U

5. HUGarrett-Mayer E, Parmigiani G, Zhong X, Cope L, Gabrielson E. Cross-study Validation and Combined Analysis of Gene

Expression Microarray Data. Johns Hopkins University, Dept. of Biostatistics Working Paper 65, 2004. U

6. HUGarrett-Mayer E, Parmigiani G. Clustering and Classification Methods for Gene Expression Data Analysis. Johns Hopkins

University, Dept. of Biostatistics Working Paper 70, 2004. U

7. HUGarrett-Mayer E. Understanding the Continual Reassessment Method for Dose Finding Studies: An Overview for Non-

Statisticians. Johns Hopkins University, Dept. of Biostatistics Working Paper 74, 2005. U

8. HUZhong X, Marchionni L, Cope L, Iversen E, Garrett-Mayer E, Gabrielson E, Parmigiani G. Optimized Cross-Study

Analysis of Microarray Based Predictors. Johns Hopkins University, Dept. of Biostatistics Working Paper 129, 2007. U

9. HUSu S-C, Caffo B, Garrett-Mayer E, Bassett S. Modified Test Statistics by Inter-voxel Variance Shrinkage with an

Application to fMRI. Johns Hopkins University, Dept. of Biostatistics Working Paper 138, 2007. U

10. HUCope L, Garrett-Mayer E, Gabrielson E, Parmigiani G. A Measure of Cross-Study. Johns Hopkins University, Dept. of

Biostatistics, Working Paper 146, 2007. U

11. Garrett-Mayer E, Wahlquist AE. A likelihood-based approach to early stopping in single arm phase II clinical trials. MUSC

Department of Public Health Sciences Working Papers 11-001, 2011.

12. O’Connell N, Garrett-Mayer E. Latent variable approach to elicit continuous toxicity scores and severity weights for

multiple toxicities in dose-finding oncology trials. MUSC Department of Public Health Sciences Working Papers 15-001,

2015.

USOFTWARE

1. Garrett ES, Hu J, Parmigiani G, Cope LC, Zhong X. POE: statistical tools for molecular classification using microarrays

(2002) HUhttp://astor.som.jhmi.edu/poe/ U

2. Zhong X, Garrett ES, Cope LC, Parmigiani G. Mergemaid: Merging and visualization tools for cross-study validation of

gene expression analyses (2004) HUhttp://astor.som.jhmi.edu/MergeMaid/ U

C COMMUNITY SERVICE

2010- 2011 Wando High School: Business Alliance Board for the School of Health Sciences, Human and Public

Services. Mt Pleasant, SC.

2013-2014 Senior Student Thesis Mentor, Academic Magnet High School, North Charleston, SC.

2014 – present Carolina Coonhound Rescue, Foster parent to homeless hounds. Charleston, SC.